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1. INTRODUCTION 
The oral route of drug administration is the most important 
method for administering drugs for systemic effects. When a new drug is 
discovered, one of the first questions, a pharmaceutical company asks is 
whether or not the drug can be effectively administered by the oral route, 
for its intended effect. The development of dosage forms especially for the 
prolonged release purpose has been a challenge to formulation scientists, 
because of many independent factors governing the absorption of the 
drug from the gastrointestinal tract and competitive objectives, that is, 
any action taken toimprove one objective or set of objectives may cause 
another objective or set of objectives to degrade.  
For example, modifying the solubility of the drug substance to 
prolong its release in the gastrointestinal tract may cause a reduction in 
the overall payload of formulation. A trial and error method of 
formulation does not allow the formulator to know how close a particular 
formulation is to the optimum solution, and finding the correct 
compromise is not straightforward and simple.  
Hence a fast screen is needed, to enable them to formulate 
intelligently. For this purpose the drug substances are categorized into 
four classes based on their solubility parameter and permeability to bio-
membranes, and such a classification system is called as a 
Biopharmaceutical Classification System (BCS).  The BCS was first 
devised in 1995, by Amidon et al. and since then it has become a 
benchmark in the regulation of bioequivalence of oral drug products.  
The BCS serves as a guiding tool for formulation scientists, for 
recommending a strategy to improve the efficiency of drug development 
by proper selection of dosage form and bioequivalence tests, to 
recommend a class of immediate release (IR) solid dosage forms, for 
which bioequivalence may be assessed based on in-vitro dissolution 
tests, and to lay the effect of excipients(s) on drug permeability.  
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The BCS guidance takes into account three major factors, 
dissolution, solubility, and intestinal permeability, which govern the rate 
and extent of drug absorption from immediate release solid dosage forms. 
The concept of BCS provides a better understanding of the relationship 
between drug release from the product and the absorption process. In 
this respect, the rate-limiting step is of primary relevance. 
The bioavailability will be affected only by the in vivo performance 
of the dosage form, if dissolution/drug release is rate limiting for the 
dosage form. In contrast, as long as the permeation through bio- 
membranes is a rate- limiting process, bioavailability and bioequivalence 
are not so dependent upon the drug release behaviour of the dosage 
form.  
Each class of the BCS is having its designated rate-limiting step 
and the possible tactics for its modification that enable the formulator to 
select and optimize a dosage form for the drug substance belonging to a 
particular class of BCS. The BCS has also been included in various 
guidance documents of regulatory importance. 
 
1.1. Biopharmaceutical Classification System: 
Biopharmaceutical Classification    System1 (BCS) guidance was 
provided by US Food and Drug  Administration  (FDA),  to  improve  the 
efficiency    of    drug    product    development process.   According   to   
which   drugs   are grouped into four major classes basing on their 
solubility and permeability. 
 
1.2.Concept behind BCS: 
The in-vivo performance of orally administered drugs depends upon 
their solubility and tissue permeability characteristics. The release rate 
or solubility of the drug substance will not be a governing parameter if 
the absorption of the drug is permeation rate limited and in such cases 
the in- vitro dissolution study can be used to demonstrate the 
bioavailability (BA) or bioequivalence (BE) of the drug product through in 
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vitro - in vivo correlation (IVIVC). On the other hand if absorption of the 
drug is dissolution rate limited that means the drug in the 
gastrointestinal fluid passes freely through the bio-membranes at a rate 
higher than it dissolves or is released from the dosage form.  
The specifically designed in-vivo study will be required in such a 
case, to access the absorption rate, and hence its bioavailability and to 
demonstrate the bioequivalence ultimately. Such a drug substance is a 
good candidate for controlled delivery provided they qualify in terms of 
their pharmacokinetics and pharmacodynamics for controlled release 
development.  
Also if a drug itself is having low solubility and a slow dissolution 
rate, the release will automatically get slower and the dosage form need 
not have an inbuilt release retardation mechanism, rather the absorption 
will now be governed by the gastric emptying rate.  
Therefore, the dosage form must be able to restrain within the 
absorption window for a sufficient time so that absorption can take 
place. In such case, a hydrodynamically balanced (floating) system or a 
mucoadhesive dosage form will serve the purpose. Hence the BCS can 
work as a guiding tool for the development of various oral drug delivery 
technologies. 
 
1.3.Characterization of Drug Moiety 
For a drug substance to be positioned in the BCS, its solubility and 
tissue permeability characteristics must be known: 
 
Solubility and Dissolution 
Dissolution is a process by which a solid substance (drug) goes 
into the solution, that is, mass transfer of molecules from the solid 
surface to the liquid phase.  The solubility is a property of substance by 
virtue of which it forms mixtures with other substances, which are 
chemically and physically homogeneous throughout. The degree of 
solubility (will be referred to as “solubility” hereafter) is the concentration 
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of the solute in a saturated solution (in equilibrium with solid/ drug) at 
any given temperature. The rate of dissolution and solubility are not the 
same. In contrast to solubility, the dissolution rate (i.e., the amount of 
solid substance that goes into the solution per unit time under standard 
conditions of temperature, pH, solvent composition, and constant solid 
surface area) is a dynamic process and better related to drug absorption 
and bioavailability. However, the rate of dissolution for a drug substance 
is proportionally related to its solubility in the dissolution medium. It has 
been investigated that unless a compound has aqueous solubility in 
excess of 1% (10 mg/ml) over the pH range 1-7 at 37°C potential 
bioabsorption problems may occur, and if the intrinsic dissolution rate is 
greater than 1 mg/cm2 /min then the absorption remains unimpeded. 
 
a) Determination of Solubility 
The solubilities are determined by exposing an excess of solid 
(drug) to the liquid in question (water/buffer) and assaying after 
equilibrium has been established. It usually takes 60 to 72 hours to 
establish equilibrium; sampling at earlier points is necessar y. 
Solubilities cannot be determined by the precipitation method because of 
the so-called metastable (solubility) zone. The pH solubility profile of the 
drug is determined at 37 ± 10°C in the aqueous medium, with pH in the 
range of 1 -7.5. A sufficient number of samples should be evaluated,to 
accurately define the pH solubility profile. A minimum of three replicate 
determinations of solubility in each pH condition should be carried out. 
Standard buffer solutions described in pharmacopoeia (B.P. 2003)  are 
considered appropriate for use in solubility studies. The concentration of 
the drug substance in the selected buffer or pH condition should be 
determined using a validated solubility-indicating assay that can 
distinguish the drug substances from their degradation products. 
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b) Determination of Permeability 
Permeability along with solubility forms the backbone of BCS that 
helps in accessing oral absorption of drug molecules. 
The various methods used for permeability screening are as 
mentioned below: 
1. Determination of o/w pH partition profile of the drug 
2. Studies of the extent of absorption inhumans - Pharmacokinetic 
mass balance and absolute bioavailability studies 
3. Intestinal permeability studies - The following tissues can be used: 
i) In-vivo intestinal perfusion studies in human 
    ii) In-vivo or in-situ perfusion studies in animals 
4. In vitro permeation studies using excised human or animal intestinal 
tissue 
5. In-vitro permeation experiments across a monolayer of cultured 
human intestinal cells 
6. Caco cell lines are derived from human colon carcinoma and used 
widely for permeability determination. The technique is expensive 
and requires specialized skills. Caco2  cell lines are about 60% 
accurate in predicting human permeability/absorption. 
7. Initial screening can also be carried out using parallel artificial 
membrane permeability analysis (PAMPA), which is carried out on 
microplates. It measures the permeation of compounds through a 
phospholipid-coated filter medium that mimics intestinal cell 
structures. 
 
1.4.Class Boundaries used in BCS 
1. A drug substance is considered highly soluble when the highest dose 
strength is soluble in £ 250 ml water over a pH range 1 to 7.5. 
2. A drug is considered highly permeable when the extent of absorption 
in humans is determined to be 90% of an administered dose, based 
on the mass balance or in comparison to an intravenous dose. 
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3. A drug product is considered to dissolve rapidly when 85% of the 
labeled amount of drug substance dissolves within 30 minutes, 
using USP apparatus I or II in a volume of 900 ml buffer solution. 
 
1.5.Selection of Dissolution Media 
The dissolution medium selected must be able to reflect the in-vivo 
conditions, to give a better in vitro - in vivo correlation (IVIVC). However 
the bile salts are present in the small intestine even in a fasted condition 
(average concentration @ 5 mM), standard buffer solutions have been 
used widely in the solubility analysis for BCS. In an attempt to duplicate 
the intestinal conditions in-vitro, two kinds of media have been designed, 
one to simulate the fasted state small intestine and the other to simulate 
fed state conditions in the small intestine. These two dissolution media 
can be used in drug discovery and development and are acceptable in 
regulatory aspects too. 
Hence for the drugs belonging to Class I and Class III (i.e.,having 
high solubility), simple aqueous dissolution media such as simulated 
gastric fluid (SGF, without enzymes) or simulated intestinal fluid (SIF, 
without enzymes) are suggested. In contrast, for Class II and IV (i.e., 
drugs with low solubility), use of biorelevant media is recommended for 
dissolution testing. For example: 
• To simulate fasting stomach condition - SGF plus surfactants 
• To simulate fed state condition – Milk with 3.5% fat 
• For fasted intestine -Low volume SIF. (For poorly soluble drugs) 
• For fed intestine – High volume SIF. (For poorly soluble weak acid 
drugs). 
The intrinsic dissolution rate can also be used as an alternative in 
BCS, especially in a case when the solubility of a drug cannot be 
accurately determined. Addition of a surfactant like sodium lauryl sulfate 
(SLS) or other surfactants may be required to mimic the solubilization in-
vitro. For example, the recommended  
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USP dissolution media for medroxy progesterone acetate tablet, 
danazol capsule, carbamazepine tablet, and flutamide tablet contain 
0.5%, 0.75%, 1.0% and 2.0% SLS (USP26-NF21S1). Further research is 
required to explore the proper selection of dissolution of media and to 
develop a uniform media reflecting the in-vivo dissolution condition. 
 
Class I: High Permeability and High Solubility  
   Ex: Propranolol, Metoprolol,Diltiazem, Verapamil 
Class II: High Permeability and Low Solubility  
     Ex: Ketoconazole, Mefenamic acid, Nifedipine, Nicardipine,  
              Felodipine, Piroxicam 
Class III: Low permeability and High solubility  
      Ex:    Acyclovir,    Neomycin    B,    Captopril, Enalaprilate,  
              Alendronate. 
Class IV: Low permeability and Low solubility 
      Ex: Chlorthiazide, Furosemide, Tobramycin. 
 
1.6.Purpose of the BCS Guidance 
1. Expands the regulatory application of the  BCS  and  recommends 
methods for classifying drugs. 
2. Explains when a waiver for in vivo bioavailability and bioequivalence 
studies may be requested based on the approach of BCS. 
 
1.7.Goals of the BCS Guidance 
1. To improve the efficiency of drug development and the review process 
by recommending   a   strategy   for identifying expendable clinical 
bioequivalence tests. 
2. To recommend a class of immediate- release (IR) solid oral dosage 
forms for which bioequivalence may be assessed based on in vitro 
dissolution tests. 
3. To    recommend    methods    for classification   according   to   
dosage form dissolution, along with the solubility and permeability 
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characteristics of the drug substance. The classification is associated 
with drug dissolution  and  absorption model,  which identifies the 
key parameters controlling drug absorption as a set of dimensionless 
numbers: 
4. The Absorption Number (An) is the ratio of the Mean Residence 
Time (Tres) to the Mean Absorption Time (Tabs) and it could be 
estimated using equation. 
An = (Tres / T abs) = (3.14R2L/Q) (R/Peff) …… . (2) 
5. The Dissolution number is a ratio of mean residence time to 
mean dissolution time. It could be estimated using equation 2. 
6. The   Dose   number   is   the   mass divided by an uptake 
volume of 250 ml and the drug’s solubility. It could be estimated 
using equation 2. 
D0 = Dose/(V0 xC mins) …………(4) 
7. The  mean  residence time:  here  is the average of the 
residence time in the stomach, small intestine and the colon. 
Where: L = tube length, R = tube radius, π =3.14, Q =fluid 
flow rate, ro = initial particle radius, D = particle acceleration, ρ = 
particle density, Peff = effective permeability, Vo is the initial gastric 
volume equal to 250 ml which is derived from typical bioequivalence 
study protocols that prescribe administration of a drug product to 
fasting human volunteers with a glass of water at the time of drug 
administration and Cs min is minimum  aqueous  solubility  in  the 
physiological pH range of 1-8. 
Techniques for Solubility Enhancement. 
1)   Chemical Modification 
1. Salt Formation 
2. Co-crystallization 
3. Co-solvency 
4. Hydrotropic 
5. Solubilizing agent 
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6. Nanotechnology 
2)   Physical Modifications 
1. Particle size reduction 
2. Modification of the crystal habit 
3. Complexation 
4. Solubilization by surfactants 
5. Drug dispersion in carriers  
a. Solid solution 
b. Eutectic mixtures  
c. Solid dispersion 
3)   Other 
1. Supercritical fluid method 
2 .  Spray  freezing  into  liquid  and  Lyophillization 
3. Evaporative    precipitation    into aqueous solution 
4. Solvent evaporation method 
5. Hot melt extrusion 
6. Electrostatic spinning method 
7. Direct capsule filling 
8. Polymeric Alteration 
9. High- Pressure Homogenization 
10. Lyophilization technique 
11. Inclusion Complexes: 
a) Kneading Technique  
b) Co-precipitation 
c) Neutralization  
d) Co-grinding 
e) Spray-Drying Method 
f) Microwave Irradiation Method 
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1.8.Extension to BCS: (BCS containing six classes) 
Bergstrom et al. devised a modified Biopharmaceutical 
Classification System, in which they categorized the drugs into six 
classes based on the solubility and permeability.  The solubility was 
classified as “high” or “low” and the permeability was allotted as “low”, 
“intermediate,” or “high”. This new classification was developed based on 
the calculated surface area descriptors on the one hand and solubility 
and permeability on the other. Surface areas related to the nonpolar part 
of the molecule resulted in good predictions of permeability. It was 
tentatively concluded that these models would be useful for early 
indication with regard to the absorption profiles of the compound during 
the early stages of drug discovery so that the necessary modifications can 
be made to optimize the pharmacokinetic parameters.  
 
1.9.Application of BCS in Oral Drug Delivery Technology 
Once the solubility and permeability characteristics of a drug are 
known, the formulation scientist can then, based on BCS, easily decide 
which drug delivery technology will best help in getting the optimum 
pharmacokinetic characteristics. The major challenge in the development 
of drug delivery systems for a class I drug is to achieve a targeted release 
profile associated with the particular pharmacokinetic and 
pharmacodynamic properties. Formulation approaches include both the 
control of release rate and physiochemical properties of drugs like the 
pH-solubility profile of the drug. 
The systems that are developed for class II drugs are based on the 
micronization, lyophilization, addition of surfactants, formulation as 
emulsions and microemulsion systems, use of complexing agents like 
cyclodextrins, and so on. Class III drugs are required for technologies 
that address the fundamental limitations of absolute or regional 
permeability. Peptides and proteins constitute, solely, the class III drugs; 
these are now the center of focus for research in drug delivery. The class 
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IV drugs present a major challenge for the development of drug delivery 
systems and the route of choice, due to their poor solubility and 
permeability characteristics. These are often administered by parenteral 
route with the formulation containing solubility enhancers. 
 
1.10.BCS as a Framework for Optimization of a New Chemical Entity 
The BCS provides a clue about the pharmacokinetics of the drug 
(NCE), any newly synthesized or identified chemical molecule that is 
proved to be therapeutically active, but is still under investigation for 
formulation development and final approval, which provides an 
opportunity to the synthetic chemist or the drug designer to manipulate 
in the chemical structure of the drug entity so as to optimize the 
physicochemical parameters of the lead molecule for desired drug 
delivery and targeting characteristics.  
The synthetic chemist and formulation scientists act together 
toachieve better ‘deliverability’ directed toward the desired 
pharmacokinetics and therapeutic efficiency right from the initial stages 
of drug design, to fulfill the propelled need for “High Throughput 
Pharmaceutics (HTP)”. Lipinski et al. has suggested a ‘rule of 5,’ which 
has been widely adopted by the pharmaceutical industry as a yard stick 
for screening out compounds that are likely to have poor absorption 
profiles. According to this rule the poor absorption or permeation is more 
likely when: 
• There are more than five H-bond donors (expressed as a sum of 
hydroxyl and N-H linkage). 
• The molecular weight of the drug moiety is more than 500 
• The log P is over % 
• There are more than 10 H-bond acceptors 
Compounds that are substrates for the biological transporters are 
an exception to the rule. 
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1.11.Mouth dissolving tablet (MDT): 
Mouth dissolving tablet (MDT) It  is  a  tablet that  disintegrates  
and  dissolves  rapidly  in  the  saliva,  within a few seconds without the 
need of drinking water or chewing.  A mouth dissolving tablet usually 
dissolves in the oral cavity within 15s to 3 min. Most of the MDTs include 
certain super disintegrants  and taste masking agents.    
Ideal properties of MDT:  
A Mouth Dissolving Tablet should  
a. Not require water or other liquid to swallow.   
b. Easily dissolve or disintegrate in saliva within a few seconds.  
c. Have a pleasing taste.   
d. Leave  negligible  or  no  residue  in  the  mouth  when  
administered.   
e. Be portable and easy to transport.   
f. Be  able  to  be  manufactured  in  a  simple  conventional  
manner  within low cost.   
g. Be less sensitive to environmental conditions like temperature, 
humidity etc. 
Advantages of MDT:  
a. No need of water to swallow the tablet.    
b. Can  be  easily  administered  to  pediatric,  elderly  and  mentally  
disabled patients.   
c. Accurate dosing as compared to liquids.   
d. Dissolution and absorption of drug is fast, offering rapid onset  of 
action.   
e. Bioavailability  of  drugs  is  increased as  some  drugs  are  
absorbed  from mouth,  pharynx  and  esophagus  through  saliva  
passing down into the stomach  
f. Advantageous  over  liquid  medication  in  terms  of  
administration as well as   
g. transportation        
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h. First  pass  metabolism  is  reduced,  thus  offering  improved  
bioavailability and thus  reduced dose and side effects.   
i. Free  of  risk  of  suffocation  due  to  physical  obstruction  when  
swallowed, thus   
j. offering improved safety.   
k. Suitable for sustained/controlled release actives. 
l. Allows high drug loading. 
1.12.Methods for the Formulation of Mouth Dissolving Tablets 
             Various processes employed in formulating MDTs are described 
below. 
A.Patented Technologies 
1. Zydus Technology 
      This technology involves physical trapping of drug in a matrix 
composed of a saccharide and a polymer .The polymer generally used are 
partially hydrolyzed gelatin, hydrolyzed dextran, dextrin, alginate, 
polyvinyl alcohol, polyvinyl pyrrolidone, acacia and these mixtures. The 
methodology involves solution or dispersion of components is prepared 
and filled in to blister cavities, which are frozen in a liquid nitrogen 
environment. The frozen solvent is removed or sublimed to produce 
porous wafers. Peelable backing is used to pack zydis units. These 
formulations are sensitive to moisture and may degrade at humidity 
greater than 65% zydis is patented by R.P. Scherer. 
 
2. LYOC 
         Oil in water emulsion is prepared and placed directly in to blister 
cavities followed by freeze drying. Non homogeneity during freeze drying 
is avoided by incorporating inert filler to increase the viscosity finally the 
sedimentation. The methodology is patented by pharmalyoc. 
 
3. Quick Solv 
        Methodology includes dissolving matrix components in water and 
the solution or dispersion is frozen. Then dry the matrix by removing 
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water using an excess alcohol (solvent extraction). The product formed 
has uniform porosity and adequate strength for handling. This 
technology patented by Jassen Pharmaceuticals. 
 
4. Nanocrystal Technology 
        Nano crystal technology includes lyophilization of colloidal 
dispersion of drug and water soluble ingredients filled into blister 
pockets. This method avoid manufacturing process such as granulation, 
blending and tableting. This method is advantageous for highly potent 
and hazards drugs, manufacturing losses are negligible and the process 
is small quantities of drugs. This methodology is patented by Elanking of 
Prussia. 
 
5. Flash Tab Technology 
          This technology includes granulation of excipients by wet 
granulation method and follow by compressing in to tablets excipients 
used in this technology are of two types. Disintegrating agents include 
reticulated polyvinyl pyrolidone or carboxy methyl cellulose, starch, 
modified starch, microcrystalline cellulose, carboxy methylated starch, 
etc. tablets formed have satisfactory physical resistance. Disintegration 
time is within 1 minute. This methodology patented by Ethypharm, 
France. 
 
6. Orasolv Tecnology  
           This includes use of effervescent disintegrating agents 
compressed with low pressure to produce MDTs. The evaluation of 
carbon dioxide from the tablet produces fizzing sensation, which is a 
positive organoleptic properties. Concentration of effervescent mixed 
usually employed is 20-25%of tablet weight .as the tablets prepared at 
low compression force, they are soft and fragile in nature. This is 
initiated to develop paksolv, a special packaging to protect tablets during 
storage and transport. Paksolv is dome-shaped blister package, which 
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prevents vertical movements of tablets in the depression. This offers 
moisture, light and child resistance packing. 
 
7. Durasolv Tecnology    
            This methodology utilized conventional tableting equipment and 
tablets are formulated by using drug non-direct compression fillers and 
lubricants. Non direct compression fillers are dextrose mannitol, sorbitol, 
lactose, and sucrose which have advantages of quick dissolution avoid 
gritty structure (which is generally present in direct compressible 
sugar)The tablets formed are strong and can be packed in conventional 
packing in bottles and blisters. Nondirect compressible fillers generally 
used in the range of 60-95%,lubricants in 1-2.5%.this technology 
patented by CIMA labs. Durasolv products include Nulev 
(hyoscyaminesulphate),Zoming ZMT(Zolmitraptan). 
 
 
8. Wow Tab Tecnology 
 This technology utilizes conventional granulation and tableting 
methods to produce MDTs employing low-and high moldability 
saccharides. WOW means with out water. Low moldabilty saccharides 
are lactose, mannitol, glucose, sucrose and xylitol. High moldability 
saccharides are maltose, maltitol, sorbitol and oligosaccharides. When 
these  two type saccharides used alone tablets obtained do not have 
desired properties of rapid disintegration and hardness, so combination 
are used. This technology involves granulation of low-moldable 
saccharieds as a binder and compressing in to tablets followed by 
moisture treatment. So the tablets formed showed adequate hardness 
and  rapid disintegration .this technology patented by Yamanouchi. 
WOW tab product include Benadryl allergy and sinus fast melt (OTC). 
9. Dispersible Tablet Tecnology 
It offers development of MDT improved dissolution rate by 
incorporating 8-10% of organic acid and disintegrating agents. 
disintegrating agents facilitates rapid swelling and good  wetting results 
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in quick disintegration. Disintagrants include starch, modified starches, 
microcrystalline cellulose, alginic acid, cross linked sodium carboxy 
methyl cellulose and cyclodextrines. Combilnation of disintegarants 
improved disintegration usally less than 1 minutes. The methodology 
patented lek, Yugoslavia. 
 
10. Pharma Burst Tecnology   
It utilize co proceed exicipients to develop MDT which dissolves 
within 30-40 seconds. The technology involves dry blending of drugs, 
flavor and lubricant followed by compression in to tablets. The tablets 
obtained have sufficient strenghth so they can be packed in blister packs 
and bottles. This technology patened by SPI pharma, new castle. 
 
11. Frosta Technology  
            It utilizes the concept of formulating plastic granules and 
compressing at low pressure to produce strong tablets with high 
porosity. Plastic granules composed of porous and plastics material, 
water penetration enhancer and binder. The process involves mixing the 
porous plastic material with water penetration enhancer and followed by 
granulating with binder. The product showed excellent hardness and 
rapid disintegration within 15-30 seconds. This methodology patented by 
Akina. 
 
12. Oraquick 
        It utilize taste masking microspheres technology called as micro 
mask, which provides superior mouth feel, significant mechanical 
strength and quick disintegration and dissolution of the products. This 
process involves preparation of micro particles in the form of matrix that 
protects the drug which can be compressed with sufficient mechanical 
strength. Low heat of production in this process make it suitable for heat 
sensitive drug. The products formed dissolves within few seconds. The 
methodology patented by K.V Pharmaceuticals. 
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13. Ziplets or Advatab 
      It utilize water insoluble gradients combined one are more effective 
disintegrants to produce MDT s with improved mechanical strength and 
optimum disintegration time at low compression force. Advantage of the 
method include high drug loading, formation of coated particles and does 
not require special packaging. This technology patented by pessano con 
Bornago. 
 
14. Flashdose  
            The flash dose tablets consists of self binding shear form matrix 
termed as floss. Shear form matrices are prepared by flash heat 
processing. This technology patented by Fluzisz. Egibuprofen melt in 
mouth tablets. 
 
B.Conventional Methods     
1. Lyophilization or Freeze-Drying 
           Lyophilization is a process which includes removal of a solvent 
from a frozen suspension of drug with structure forming additives. Freeze 
drying of a drug along with additives imparts glossy amorphous 
structure resulting in highly porous and light weight product. The 
resulting  tablet has rapid disintegration and dissolution when placed on 
a tongue and the freeze dried leutin dissolves instantly to release the 
drug. MDT s formed by lyophilization have some demerits like low 
mechanical strength, poor stability at higher temperature and humidity. 
Use of expensive equipment for freeze drying is another demerits of the 
process. 
 
2. Moulding 
          Molding process include moistening, dissolving or dispersing the 
drug with a solvent then molding the moist mixer in to 
tablets(compression molding with a low pressure  than conventional 
tablet compression )evaporating the solvent from drug solution, or 
suspension at ambient pressure respectively. The molded tablets formed 
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by compression molding are air dried. As the compression force 
employed is lower than conventional tablet, the molded tablet results in 
highly porous structure, which increase the disintegration and 
dissolution of the product. To further improve the dissolution rate of the 
product powder mixer should be sieved through very fine screen. This 
process is applied usually with soluble ingredients (saccharides) which 
offer improved mouth feel and disintegration of tablets. Some of the 
demerits observed are the tablet formed by this process shows low 
mechanical strength, which results in erosion and breakage during 
handling. 
 
3. Cotton Candy Process 
         Cotton candy process involves formation of matrix of 
polysaccharides or saccharides by simultaneous action of flash melting 
and spinning. The matrix formed is partially recrystallized to have 
improved flow properties and compressability. This candy floss matrix is 
then milled and blended with active ingredients and excipients and 
subsequently compressed to MDTs. This process is so named because it 
utilizes a unique spinning mechanism to produce floss-like crystalline 
structure, which mimic cotton candy. The main merits of this method are 
the process can accommodate high doses of drug and offers improved 
mechanical strength. The main demerit is the use of high process 
temperature. 
 
4. Spray Drying 
          In this method MDTs formulated by using hydrolyzed / 
unhydrolyzed gelatin as supporting agent for matrix, mannitol as bulking 
agent and sodium starch glycolate or croscarmellose sodium as 
disintegrating agent. Disintegration and dissolution were further 
improved by adding effervescent components.ie citric acid (an acid) and 
sodium bicarbonate (an alkali). The formulation was spray dried to yield 
a porous powder. The products formed are highly porous fine powders 
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and are disintegrated in<20 seconds. Allen et al utilized this method for 
preparing MDTs. 
 
5. Mass Extrusion 
          It involves softening the active blend using the solvent mixture of 
water soluble polyethylene glycol and methanol and subsequent 
expulsion of softened mass through the extruder or syringe to get a 
cylinder of the product in to even segments using heated blade to forms 
tablets. (yadav A.V et al,2010) 
 
6. Compaction Melt Granulation 
        The method involves incorporation of hydrophilic waxy binder 
(super poly state.) PEG -6-sterate. Super poly state is a waxy material 
with an M.P of 33-37c. and an hydrophilic lipophilic balance of 9. It act 
as binder, increase the physical resistance of tablets and it helps the 
disintegration of tablets as it melt in the mouth and solubilizes rapidly 
leaving no residue. Super poly state incorporated in the formula by melt 
granulation method, where granules are formed by the molten form of 
the material. eg crystallized paracetamol was used as model drug and in 
addition mannitol added as water soluble excipient and cross carmellose 
sodium as disintegrating agents. Abdlbary et al prepared MDT by this 
method. 
 
7. Phase Transition Process 
        Kuno et al investigated disintegration of MDTs are formulated by 
sugar alcohols using erythriol (M.P 122C), xylitol (m.p 93-95), trehalose 
(97c) and mannitol (166c). This method involves compressing a powder 
containing two sugar alcohols with high and low-melting points and 
subsequent heating at temperature between their melting points. Before 
heating process the tablet do not have sufficient hardness because of low 
compatibility. The tablet hardness was increased after heating process, 
due to the increase of interparticular bonds or bonding surface area in 
tablets induced by phase transition of low melting point sugar alcohols. 
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8. Sublimation  
        The method involves addition of volatile salt to the tableting 
components, mixing and volatilizing the volatile salt creates pores  in the 
tablets come in contact with saliva. Camphor, naphthalene, urea, 
ammonium bi carbonate etc., can be used to prepare porous tablets of 
good mechanical strength. koizumi et al used mannitol as diluents and 
camphor as volatile material to prepare porous compressed tablet. The 
tablets were subjected to vaccum at 80 c for 30 minutes to eliminate 
camphor and thus form the pores in the tablet. The tablet formed have 
highly porous matrix which is the key factor for rapid disintegration. 
 
C.Other Methods   
         Other methods includes dry granulation, wet granulation and 
direct compression methods. The important components used in these 
methods are super disintegrants.  
1. Dry Granulation   
          In this technique there is no use of liquids. The process involves 
the formation of slugs. Then slugs are screened are milled to produce 
granules. The granules formed are then compressed to form tablet. 
2. Wet Granulation  
          The process involves addition of liquids to a powder in a vessel 
equipped with any type of agitation that will produce agglomeration or 
granules. These granules after drying are compressed to form tablets. 
This method have more operational manipulation and is more time 
consuming than other methods. this  method is not suitable for drugs 
which ass thermo labile or hydrolysable by presence of water in the 
liquid binder. 
3. Direct Compression 
          In direct compression method, of powder blends of active 
ingredients and suitable excipients, which will flow uniformly in the die 
cavity and formed a film compact (Banker G.S et al 1987).direct 
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compression method are very popular because it reduse the number of 
steps involved and the materials required. 
Advantages       
1. Easiest method to manufacture fast dissolving tablets. 
2. Low manufacturing cost. 
3. Use of conventional equipment and commonly available 
excipients. 
4. High quality finished product. 
Fig.No. 1: Flow sheet of direct compression 
                       DIRECT COMPRESSION METHOD 
  Drug                                                                        
  Diluent 
  Glidant                                                 Mixing 
  Disintegrant   
                                                
                
Lubricant                                                  Mixing  
                                      
 
                                       Compression mix 
                                                                         
                        File Die, Compress Tablet, Eject Tablet  
                                                           
                     Metal check, De dusting, Coating Packaging  
 
1.13.Super Disintegrants in Immediate Release Tablets 
 Super-disintegrants are effective at low concentration and have 
greater disintegrating efficiency and they are effective intra-granularly as 
well as extra-granularly. But have one drawback that it is hygroscopic 
therefore not used with moisture sensitive drugs. These super-
disintegrants act by swelling and due to swelling pressure exerted in the 
CHAPTER-1                                                                                        INTRODUCTION 
 
J.K.K.NATTRAJA COLLEGE OF PHARMACY Page 22 
 
outer direction or radial direction, it causes tablet to burst or accelerate 
the absorption of water leading to an enormous increase in the volume of 
granules to promote disintegration is shown in Fig 2.  
Fig.No. 2: Mechanisms of Super-disintegrant swelling 
 
Table.No. 1: LIST OF SUPERDISINTEGRANTS 
SUPERDISINTEGRANTS TYPE 
MECHANISM 
OF ACTION 
SPECIAL 
COMMENTS 
Croscarmellose 
Ac-Di-Sol 
Nymce ZSX 
Primellose 
Solutab 
Vivasol 
 
Crosslinked 
Cellulose 
Swells 4-8 
folds in < 10 
seconds 
 
Swelling and 
wicking both. 
Swells in two 
dimensions. 
 
Direct 
compression or 
Granulation 
Starch free 
Crospovidone 
Crospovidon M 
Kollidon 
Polyplasdone 
 
 
Crosslinked 
PVP 
Swells very 
little and 
returns to 
original size 
after 
compression 
but act by 
capillary 
action 
Water insoluble 
and 
spongy in 
nature so get 
porous tablet 
Sodium starch glycolate 
Explotab 
Primogel 
Crosslinked 
Starch 
Swells 7-12 
folds in 
<30 seconds 
Swells in three 
dimensions and 
high 
level serve as 
sustain 
release matrix 
Alginic acid NF 
Satialgine 
Crosslinked 
alginic acid 
 
 
Rapid 
swelling 
in aqueous 
medium or 
wicking 
action 
Promote 
disintegration 
in both 
dry or wet 
granulation 
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Table. No. 2: PARAMETERS INFLUENCING THE SWELLING 
BEHAVIOUR OF SUPERDISINTEGRANTS (6-8) 
1.14.Effect of excipients used in the Formulation: 
a) Effect of fillers: 
The solubility and compression characteristics of fillers affect both 
rate and mechanism of disintegration of tablet. If soluble fillers are used 
then it may cause increase in viscosity of the penetrating fluid which 
tends to reduce effectiveness of strongly swelling disintegrating agents 
and as they are water soluble, they are likely to dissolve rather than 
disintegrate. Insoluble diluents produce rapid disintegration with 
adequate amount of disintegrants. Tablets made with spray dried lactose 
(water soluble filler) disintegrate more slowly due to its amorphous 
character and has no solid planes on which the disintegrating forces can 
be exerted than the tablet made with crystalline lactose monohydrate. 
b) Effect of binder: 
         As binding capacity of the binder increases, disintegrating time of 
tablet increases and this counteract the rapid disintegration. Even the 
concentration of the binder can also affect the disintegration time of 
tablet. 
 
 
PARAMETERS EFFECTS 
Amount of 
superdisintegrant 
A minimum amount of superdisintegrant is 
necessary for the development of sufficient 
swelling to outer membrane 
Additives ( binders ) 
 
Polymeric binders can reduce swelling pressure 
by spacial separation of superdisintegrant 
particles or competition for free water 
Ionic strength of the 
medium 
Competition of the ions for free water 
pH values Swelling can be influenced for the 
superdisintegrants with ionizable 
groups(e.g:carboxylic groups in croscarmellose ) 
CHAPTER-1                                                                                        INTRODUCTION 
 
J.K.K.NATTRAJA COLLEGE OF PHARMACY Page 24 
 
c) Effect of lubricants: 
Mostly lubricants are hydrophobic and they are usually used in 
smaller size than any other ingredient in the tablet formulation. When 
the mixture is mixed, lubricant particles may adhere to the surface of the 
other particles. This hydrophobic coating inhibits the wetting and 
consequently tablet disintegration. Lubricant has a strong negative effect 
on the water uptake if tablet contains no disintegrants or even high 
concentration of slightly swelling disintegrants. On the contrary, the 
disintegration time is hardly affected if there is some strongly swelling 
disintegrant present in the tablet.    
1.15.Methods of addition of Disintegrants: 
Disintegrating agent can be added either prior to granulation 
(intragranular) or prior to compression (after granulation i.e. 
extragranular) or at both processing steps.  
Extragranular fraction of disintegrant (usually, 50% of total 
disintegrant requires) facilitates breakup of tablets to granules and the 
intragranular addition of disintegrants produces further erosion of the 
granules to fine particles. 
 
CHAPTER 2 
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2. LITERATURE REVIEW 
1. Gupta et al., described on “Fast Dissolving Tablet- A Review”. This 
review describes the various formulation aspects, superdisintegrants 
employed and technologies developed for MDTs, along with various 
excipients, evaluation tests, marketed formulation and drugs used in 
this research area. 
2. Chawla et al., described on “Mouth Dissolving Tablets: An 
Overview”. These overview deals with the gold standard in 
pharmaceutical industry are the oral delivery because it is the 
easiest, safest, economical and convenient method for the drug 
delivery. Mouth dissolving tablets have becomes the most demanding 
application during last decades and in the pharmaceutical industry 
this field has become a rapidly area. Mouth dissolving tablets during 
insertion in the mouth should have to dissolve or disintegrate in the 
mouth within 15sec to 3 minutes without the help or need of any 
drinking agent like water. These mouth dissolving tablets can be 
given anytime, anywhere to anyone who needs this without the 
presence of water and these will show the effective action in few 
minutes. 
3. Gandhi et al., studies “Mouth Dissolving Tablets: A New Venture in 
Modern Formulation Technology”. This review describes the various 
formulation aspects and technologies developed for MDTs, along with 
various excipients, evaluation tests, marketed formulations of MDTs. 
There are multiple fast dissolving OTC and Rx products on the 
market, most of which have been launched in the past 3 to 4 years. 
There have also been significant increases in the number of new 
chemical entities under development using a fast-dissolving drug 
delivery technology. Thus, in future, it is expected that this delivery 
system will get much importance as that of conventional delivery 
systems. 
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4.  Bhanja et al., studied the “Mouth Dissolving Tablets of Losartan 
Potassium: Formulation and Evaluation”.  The objective of the 
proposed research work is to prepare and evaluate the mouth 
dissolving/disintegrating tablets (MDTs) of losartan Potassium, which 
avoid the first-pass metabolism, improved the dissolution rate and 
enhance the bioavailability. Mouth dissolving tablets (MDTs) were 
prepared by direct compression method by using combination of 
superdisintegrant like Ac-Di-Sol and Polyplasdone-xl 
(1%,2%,3%&4%). and evaluated for physico-chemical evaluation 
parameter such as hardness, friability, weight variation, drug content 
uniformity, water absorption ratio, wetting time, in-vitro and in-vivo 
disintegration time, in-vitro dissolution studies. The twelve 
formulations, B1to B8 were formulated and among these 
formulations, B8 was optimized. 
5. Shah et al., described on “Formulation Development and Evaluation 
of Mouth Dissolving Tablet of Tramadol Hydrochloride”. The aim of 
this study was to formulate FDTs with sufficient mechanical integrity 
and to achieve faster disintegration in the oral cavity without water. 
To achieve this goal, mannitol used as diluent and aspartame as 
sweetening agent for the formulation of tablets. Attempts were made 
to enhance dissolution rate along with faster disintegration using 
superdisintegrants, like croscarmellose sodium, sodium starch 
glycolate and crospovidone. Tramadol hydrochloride, a centrally 
acting synthetic opioid analgesic, was selected as the active 
pharmaceutical ingredient in the study. 
6. Kalia et al., studied the “Formulation and Evaluation of Mouth 
Dissolving Tablets of Oxcarbazepine”.  The present investigation was 
undertaken with a view to develop mouth-dissolving tablets of 
oxcarbazepine, which offers a new range of product having desired 
characteristics and intended benefits. In this study, the mouth 
dissolving tablets were prepared using two different technologies, 
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direct compression method and solid dispersion technology. Tablets 
produced by direct compression method contain crospovidone as a 
superdisintegrant and aspartame as a sweetener. Oxcarbazepine 
solid dispersions with polyvinylpyrrolidone K-30 in 1:2 ratios of drug: 
carrier showed maximum drug release and hence, compressed along 
with other excipients into mouth dissolving tablet. The results 
compared for both the technologies showed that the oxcarbazepine 
tablets prepared using solid dispersion technology was found to have 
good technological properties and satisfying and reproducible drug 
dissolution profiles. 
7. Kaur et al., focused on “Mouth Dissolving Tablets: A Novel Approach 
to Drug Delivery”. This review focused on Recent advances in Novel 
Drug Delivery Systems (NDDS) aim for designing dosage forms, 
convenient to be manufactured and administered, free of side effects, 
offering immediate release and enhanced bioavailability, so as to 
achieve better patient compliance. Though oral drug delivery 
systems, preferably, tablets are the most widely accepted dosage 
forms, for being compact, offering uniform dose and painless delivery. 
This is seen to afflict nearly 35% of the general population and 
associated with a number of conditions, like parkinsonism, mental 
disability, motion sickness, unconsciousness, unavailability of water 
etc. To overcome such problems, certain innovative drug delivery 
systems, like ‘Mouth Dissolving Tablets’ (MDT) have been developed.  
8. Ashish et al., studied the “Mouth Dissolving Tablets: A Review”. This 
current paper studied the MDTs were developed with an aim of 
having sufficient hardness, integrity and faster disintegration without 
water. Some tablets are designed to dissolve in saliva remarkably 
fast, within a few seconds, and are true fast-dissolving tablets. 
Others contain agents to enhance the rate of tablet disintegration in 
the oral cavity, and are more appropriately termed fast-disintegrating 
tablets, as they may take up to a minute to completely disintegrate. 
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This tablet format is designed to allow administration of an oral solid 
dose form in the absence of water or fluid intake. Such tablets readily 
dissolve or disintegrate in the saliva generally within <60 seconds. 
9. Prasanthi et al., studied the “Formulation and Evaluation of 
Sitagliptin Phosphate and Simvastatin Bilayered Tablets”. In general 
the work deals with the combine formulation and evaluation of 
bilayered tablets of DPP-4 inhibitor i.e., sitagliptin phosphate and 
HMG-CoA reductase i.e., simvastatin. Ten formulations of sitagliptin 
phosphate and simvastatin bilayered tablets were prepared by 
varying the ratios of polymers in the sitagliptin phosphate layer and 
simvastatin layer F1 to F10 by direct compression method. FTIR 
studies revealed there is no interaction between the drugs i.e., 
sitagliptin phosphate and simvastatin and the polymers such as 
pregelatinised starch, potato starch and sodium starch glycolate. The 
physical appearance was good and elegant. The weight variation, 
friability and hardness of tablets were found to be within USP limits. 
In-vitro drug release for sitagliptin phosphate and simvastatin of all 
formulations of F1 to F10 was carried out in phosphate buffer pH 6.8 
dissolution media. Among all the formulations F7 was optimized as 
best formulation. 
10. Heda et al., worked on “Development of Granisetron Hydrochloride 
Fast Dissolving Tablets”. The purpose of study was development of 
fast dissolving Granisetron Hydrochloride (GRA) tablets using 
suitable disintegrating agent. Comparative effect of incorporation of 
superdisntegrants and conventional disintegrant at same 
concentrations, on disintegration and dissolution was studied. The 
superdisintegrants used were sodium starch glycolate (SSG) and 
Kyron_ T-314 (Polacrillin potassium) while sodium alginate (SA) was 
used as representative conventional disintegrant. The tablets were 
prepared by wet granulation method. The disintegration times were 
lower and dissolution profile of GRA was comaparatively better with 
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the batches containing SSG compared to other disintegrating agents. 
The granisetron tablets with 3% SSG shows lower disintegration time 
than Kyron_ T-314 and SA. 
11. Patil et al., studie the “Formulation and Evaluation of Fast 
Dissolving Tablets of Granisetron Hydrochloride by Dry Grnulation 
Method”. The aim of work is to characterization and evaluation of fast 
dissolving tablet of Granisetron hydrochloride using three 
superdisintegrants like crosscarmellose sodium, crosspovidone and 
sodium starch glycolate. FTIR studies revealed that there was no 
physico-chemical interaction between granisetron hydrochloride and 
other excipients. The tablets were prepared by dry granulation 
method and all had the same amount of ingredients except, the 
superdisintegrant level. Tablet containing crosspovidone showed 
excellent disintegration time and drug release as compared to other 
formulations.  
12. Reichal et al., described on “Design and Evaluation of Fast 
Dissolving Tablets of Sitagliptin Phosphate Monohydrate”.  The core 
objective of the study was to design and evaluate fast dissolving 
tablets of Sitagliptin Phosphate Monohydrate. Fast dissolving or 
disintegrating tablets were prepared by wet granulation by using 
starch Glycolate, Microcrystalline Cellulose, Cross carmellose 
Sodium as superdisintegrants. The prepared tablets were evaluated 
for pre - compression and post compression parameters. The in-vitro 
release studies were carried out by using USP Type II dissolution 
apparatus. The selected optimized batches were kept for stability 
studies at 40 °C /75%± 5%RH for a period of three months. All the 
results obtained were found to be satisfactory and within the limits. 
The results of in-vitro drug release study showed that formulation F6 
exhibited good and fast disintegrating time within 12 seconds. 
13. Nagendrakumar et al., studied on “Design of Fast Dissolving 
Granisetron Hcl Tablets Using Novel Co –Processed 
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Suprdisintegrants”. In the present work, fast dissolving tablets of 
granisetron HCl were prepared using novel co-processed 
superdisintegrants consisting of crospovidone and sodium 
starchglycolate in the different ratios (1:1, 1:2 & 1:3). The developed 
superdisintegrants were evaluated for angle of repose, Carr’s index 
and Hausner’s ratio in comparison with physical mixture of 
superdisintegrants. The angle of repose of the developed excipients 
was found to be < 25o, Carr’s index in the range of 10-15% and 
Hausner’s ratio in the range of 1.11-1.14. Based on in vitro 
dispersion time (approximately 20 sec), promising formulation CP1 
was tested for in vitro drug release pattern in pH 6.8 Phosphate 
buffer and short-term stability (at 400C/75% RH for 3 months), drug 
excipients interaction (IR spectroscopy) were studied. Among the 
designed formulations, the formulation (CP1) containing 4% w/w of 
co-processed superdisintegrant (1:1 mixture of crospovidone and 
sodium starchglycolate) emerged as the overall best formulation 
(t50% 2.0 min) based on drug release characteristics in pH 6.8 
phosphate buffer compared to commercial conventional tablet 
formulation (t50% >15 min). 
14. Keerthi et al., described on “Formulation and Evaluation of 
Sitagliptin Phosphate Gastro Retentive Tablets”. The purpose of the 
present investigation is to formulate a novel gastro retentive system, 
floating tablets of Sitagliptin Phosphate, an anti diabetic agent by 
direct compression technique using lactose as diluent. The drug-
excipients interaction was ruled out through FTIR studies. Nine 
formulations of Sitagliptin Phosphate tablets were prepared using 
HPMC K100 and HPMC K4M as release retarding agents in different 
concentrations of 10, 15 and 20% w/w. The prepared batches were 
evaluated for organoleptic properties, hardness, friability, weight 
variation and in vitro drug release. All the formulations showed low 
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weight variation with rapid dispersion time and rapid in vitro 
dissolution. 
15. Pani et al., studied on “Formulation, development, and optimization 
of immediate release nateglinide tablets by factorial design”. In the 
present study, selection of superdisintegrants among sodium starch 
glycolate, cross povidone, Starch-1500 and cross carmellose sodium 
(CCS) was carried out for development of immediate release 
nateglinide tablets (NTG). The results revealed that CCS was the best 
superdisintegrant for the development of immediate release tablets of 
NTG. The sign of the coefficient of the polynomial equation signified 
that the disintegration time was decreased and DR0.5h was 
increased by decreasing the hardness of the tablets as well as by 
increasing the concentration of CCS in the tablets. A checkpoint 
batch of the tablets was prepared by changing the value of 
independent variables within the range used in the preparation of 
factorial batches of tablets to check the validity of the evolved 
optimized mathematical model. 
16. Dahiya et al., studied the “Formulation and Evaluation of 
Granisetron Hydrochloride Orodispersible Tablets”. The object of the 
present work was to formulate and evaluate orodispersible tablets of 
granisetronm hydrochloride, a highly water soluble, tasteless, 
antiemetic drug employing superdisintegrants explotab, 
crospovidone, Ac-Di-Sol. The mix powder blends of varying 
compositions were prepared and evaluated for micromeritic 
properties and then subjected to tablet preparation by direct 
compression method. The prepared tablets were evaluated for 
physical parameters, wetting time, disintegration time, content 
uniformity and in vitro dissolution. The physical parameters were 
found satisfactory and the disintegration time of tablets was found 
between 19 to 35 seconds which is well below the limit of 
disintegration time by European Pharmacopoeia.  
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17. Ponugoti et al., described on “Formulation and Evaluation of Mouth 
Dissolving Tablets of Tramadol Hydrochloride”. Tramadol HCl MDT 
were prepared by direct compression using Pharmaburst as 
coprocessed excipient and compared with a reference product (Rybix 
ODT, 50 mg). Physicochemical parameters including hardness, 
friability, weight variation, disintegration time and dissolution 
studies were determined for all the formulations. In-vivo studies were 
performed for the optimized formulation (F13), using as reference, a 
commercial product (Trambax IR, 50 mg), by a two-way crossover 
design under fasting conditions on eight healthy adult human 
subjects. Drug-plasma concentrations obtained from the 
bioequivalence study for test and reference products were analyzed in 
each subject by high performance liquid chromatography (HPLC), 
and basic pharmacokinetic parameters, including Cmax, Tmax, 
AUC0-t, AUC0-∞, t½ and λz, were calculated.T he tablet formulation 
prepared with Pharmaburst (F13) showed good flow properties, low 
disintegration time (15 s) and improved drug release (99 % at 30 min) 
compared with those of the reference product (88 % at 30 min) and 
passed 6 months accelerated stability test. Bioequivalence of the test 
product with that of the reference product under fasting conditions 
was established by computing 90 % confidence interval for the In-
transformed pharmacokinetic parameters of Cmax, AUC0-t and 
AUC0-∞ for tramadol. 
18.  Harita et al., studied the “A Short review on Mouth dissolving 
tablet”. The main aim of floating drug delivery system is to develop a 
new dosage form which is convenient in administration and 
manufacturing, should free from side effects and should exhibit 
immediate release with better patient compliance and enhanced 
bioavailability. Tablets are the most widely accepted dosage forms in 
oral drug delivery system due to its numerous advantages. But 
beside the advantages there a few disadvantages like sudden 
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exposure of allergies, mental disability, motion sickness, 
unconsciousness, lack of water etc. In order to overcome such 
difficulties new drug delivery systems like fast dissolving tablets were 
developed.  
19. Shravani et al., studied the “Formulation and Evaluation of Fast 
Dissolving tablets of Montelukast sodium using Co-Processed 
Superdisintegrants”.  In the present work, fast dissolving tablets of 
Montelukast Sodium were prepared using novel coprocessed 
superdisintegrants consisting of crospovidone along with 
croscarmellose sodium, and crospovidone along with sodium starch 
glycolate in the different ratios (1:1, 1:2 and 1:3). Effect of co-
processed superdisintegrants on wetting time, disintegrating time, 
drug content, and in-vitro release have been studied. The prepared 
tablets formulations were evaluated for post-compressional 
parameters. All the postcompressional parameter are evaluated were 
prescribed limits and results were within IP acceptable limits. The in-
vitro disintegration time of fast dissolving tablets were found to be 
12.06 to 39.14 sec. which is in the range of fulfilling the official 
requirements. The tablet shows the t50% and t90%between 0.94 min 
to 1.82 min and 3.61 min to 5.83 min respectively. Among all 
formulations CP3 showed 99.79% drug release within 4 min. It can 
be concluded from the present work that co-processed 
superdisintegrants of crosscarmellose sodium + crospovidone are 
superior to crospovidone + sodium starch glycolate co-processed 
superdisintegrants used in Montelukast Sodium fast dissolving 
tablets. 
20. PATEL et al., studied on “Formulation and Evaluation of Mouth 
Dissolving Tablets of Cinnarizine”. The purpose of this research was 
to develop mouth dissolve tablets of cinnarizine by effervescent, 
superdisintegrant addition and sublimation methods. All the three 
formulations were evaluated for disintegration time, hardness and 
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friability, among these superdisintegrant addition method showed 
lowest disintegration time; hence it was selected for further studies. 
Further nine batches (B1-B9) were prepared by using crospovidone, 
croscarmellose sodium and L-HPC in different concentrations such 
as 5, 7.5 and 10%. All the formulations were evaluated for weight 
variation, hardness, friability, drug content, in vitro disintegration 
time, wetting time, in vitro dissolution. Formulation with 10% L-HPC 
showed the less disintegration time (25.3 s) and less wetting time 
(29.1 s). In vitro dissolution studies showed total drug release at the 
end of 6 min. 
21. Khanna et al., reviewed on “Fast Dissolving Tablets- A Novel 
Approach”. In the present scientific scenario the drug delivery 
technology has become highly competitive and rapidly evolving with 
ever increasing demand. Fast dissolving tablet (FDT) is one such type 
of an innovative and unique drug delivery system which is swiftly 
gaining much attention in the research field of rapid dissolving 
technology. Oral route is the most expedient and safest route of drug 
delivery because of wide range of drugs are administered through 
this route. Recently researchers have developed fast dissolving tablet 
(FDT) which dissolve or disintegrate rapidly in mouth saliva without 
intake of water. When compared with conventional dosage form FDT 
can be a useful alternative as well.  
22. Saroha et al., studied the “Mouth dissolving tablets: An overview on 
future compaction in oral formulation technologies”. This article 
reviews the earlier applications and methodologies of taste masking 
and also emphasize on the recent developments and approaches of 
bitterness reduction for orally used pharmaceuticals. Apart from the 
conventional methods of fabrication, this review also provides the 
detailed concept of some unique patents; technologies developed and 
marketed formulations of Mouth Dissolving Tablets (MDTs). 
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3. AIM AND OBJECTIVES 
 
➢ The present study is planned to develop Lercanidipine 
Hydrochloride into immediate release tablets by direct 
compression Method. 
➢ Lercanidipine Hydrochloride, Lercanidipine, a dihydropyridine 
calcium-channel blocker, is used alone or with an angiotensin-
converting enzyme inhibitor, to treat hypertension, chronic 
stable angina pectoris, and Prinzmetal's variant angina. 
➢ Lercanidipine Hydrochloride have biological half-life of 8-10 
hours and duration of action upto ≥ 24 hours. 
➢ Lercanidipine Hydrochloride oral bioavailability is less than 
10% due to its first pass metabolism. 
➢ Lercanidipine Hydrochloride came under BCS class II having 
poor solubility and high permeability. 
➢ The above said properties/characteristics which make 
Lercanidipine Hydrochloride suitable candidate for oral 
dissolving or mouth dissolving tablets.  
➢ In this study, we tried to prepare Lercanidipine Hydrochloride 
MDT by using various types of disintegrants by direct 
compression method. 
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4. PLAN OF WORK 
 
❖ Literature survey.  
❖ Procurement of drug, polymer and other excipients. 
❖ Preformulation Studies 
▪ Solubility 
▪ Drug and excipient compatibility studies by FTIR     
▪ Bulk density 
▪ True density  
▪ Melting point determination  
▪ Carr’s index  
▪ Hausner’s ratio 
▪ Angle of repose 
❖ Formulation development  
❖ Evaluation Studies 
• Weight variation 
• Hardness 
• Friability 
• Thickness 
• Disintegration time 
• Content uniformity 
• Wetting time and water absorption ratio 
• Invitro Dissolution study 
• Stability Studies 
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5. DISEASE PROFILE 
5.1. HYPERTENSION 
Hypertension also known as high blood pressure or arterial 
hypertension, is a chronic medical condition in which the blood 
pressure in the arteries is elevated. Blood pressure is expressed by 
two measurements, the systolic and diastolic pressures, which are the 
maximum and minimum pressures, respectively, in the arterial 
system. The systolic pressure occurs when the left ventricle is most 
contracted, the diastolic pressure occurs when the left ventricle is 
most relaxed prior to the next contraction. Normal blood pressure at 
rest is within the range of 100–140 mmHg systolic and 60–90 mmHg 
diastolic. Hypertension is present if the blood pressure is persistently 
at or above 140/90 millimeters mercury (mmHg) for most adults; 
different criteria apply to children. 
Table.No.3: Blood Pressure normal and Hypertension 
Classification 
Systolic 
pressure 
Diastolic 
pressure 
mmHg mmHg 
Normal 90–119 60–79 
High normal or pre-hypertension 120–139 80–89 
Stage 1 hypertension 140–159 90–99 
Stage 2 hypertension ≥160 ≥100 
Isolated systolic hypertension ≥140 <90 
 
Fig. No.3 : Difference between Normal and Hypertension. 
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5.1.1.Risk factors 
A number of risk factors increase the chances of having 
hypertension. 
• Age: Hypertension is more common in people aged over 60 
years. With age, blood pressure can increase steadily as the 
arteries become stiffer and narrower due to plaque build-up. 
• Ethnicity: Some ethnic groups are more prone to hypertension. 
• Size and weight: Being overweight or obese is a key risk factor. 
• Sex: The lifetime risk is the same for males and females, but 
men are more prone to hypertension at a younger age. The 
prevalence tends to be higher in older women. 
• Existing health conditions: Cardiovascular disease, diabetes, 
chronic kidney disease, and high cholesterol levels can lead to 
hypertension, especially as people get older. 
•  Too much salt (sodium) in diet. Too much sodium in diet can 
cause body to retain fluid, which increases blood pressure.  
• Too little potassium in diet. Potassium helps balance the 
amount of sodium in cells. If don't get enough potassium in diet 
or retain enough potassium, it may accumulate too much 
sodium in blood.  
• Too little vitamin D in diet. It's uncertain if having too little 
vitamin D in diet can lead to high blood pressure. Vitamin D 
may affect an enzyme produced by kidneys that affects blood 
pressure.  
•  Drinking too much alcohol. Over time, heavy drinking can 
damage heart.  
• Stress. High levels of stress can lead to a temporary increase in 
blood pressure.  
• Not being physically active. People who are inactive tend to 
have higher heart rates. The higher heart rate, the harder heart 
must work with each contraction and the stronger the force on 
arteries.  
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• Using tobacco. chewing tobacco immediately raise blood 
pressure temporarily, but the chemicals in tobacco can damage 
the lining of artery walls.  
• Certain chronic conditions. Certain chronic conditions also 
may increase risk of high blood pressure, such as kidney 
disease, diabetes and sleep apnea. 
5.1.2.Symptoms of severe hypertension can include: 
Headaches, Shortness of Breath, Nosebleeds, Flushing, 
Dizziness, Chest Pain, Visual Changes, Blood In The Urine, These 
symptoms require immediate medical attention. 
Fig. No.4 : Hypertension Symptoms. 
 
5.1.3.Pathophysiology 
Hypertension is a chronic elevation of blood pressure that, in 
the long-term, causes end-organ damage and results in increased 
morbidity and mortality. Blood pressure is the product of cardiac 
output and systemic vascular resistance. It follows that patients with 
arterial hypertension may have an increase in cardiac output, an 
increase in systemic vascular resistance, or both. In the younger age 
group, the cardiac output is often elevated, while in older patients 
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increased systemic vascular resistance and increased stiffness of the 
vasculature play a dominant role. Vascular tone may be elevated 
because of increased α-adrenoceptor stimulation or increased release 
of peptides such as angiotensin or endothelins. The final pathway is 
an increase in cytosolic calcium in vascular smooth muscle causing 
vasoconstriction. Several growth factors, including angiotensin and 
endothelins, cause an increase in vascular smooth muscle mass 
termed vascular remodelling. Both an increase in systemic vascular 
resistance and an increase in vascular stiffness augment the load 
imposed on the left ventricle, this induces left ventricular hypertrophy 
and left ventricular diastolic dysfunction. 
Fig. No.5 : Main Complications of Hypertension. 
 
5.1.4.Treatment 
The ultimate goal in treatment of the hypertensive patient is to 
achieve the maximum reduction in the long-term total risk of 
cardiovascular morbidity and mortality. This requires: 
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➢ Treatment of all reversible risk factors identified including 
smoking, dyslipidaemia  and diabetes mellitus, 
➢ Appropriate management of associated clinical conditions such 
as congestive heart failure, coronary artery disease, peripheral 
vascular disease and transient ischaemic attacks, 
➢ Achieving office blood pressure values <130/80 mmHg for 
patients with diabetes mellitus or chronic renal disease. When 
home or ambulatory pressure measurements are used to 
evaluate the efficacy of treatment, daytime values around 10–15 
mmHg lower for systolic blood pressure and 5–10 mmHg lower 
for diastolic blood pressure are the goal values.  
Treating systolic and diastolic blood pressure to target is 
associated with a decrease in cardiovascular complications. This 
includes 35%–40% mean reduction in stroke incidence, 20%–25% 
mean reduction in myocardial infarction and >50% mean reduction in 
heart failure. 
There are several strategies for achieving therapeutic goals: 
lifestyle modifications, pharmacological modifications and general 
strategies for hypertensive therapy.  
5.1.5.Lifestyle changes to treat high blood pressure 
• Eating a healthier diet with less salt (the Dietary Approaches to 
Stop Hypertension, or DASH, diet) 
• Exercising regularly 
• Quitting smoking 
• Limiting the amount of alcohol drink 
• Maintaining a healthy weight or losing weight if overweight or 
obese. 
5.1.6.Medications 
People with blood pressure higher than 130 over 80 may use 
medication to treat hypertension. Drugs are usually started one at a 
time at a low dose. Side effects associated with antihypertensive drugs 
are usually minor. Eventually, a combination of at least two 
antihypertensive drugs is usually required. 
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A range of drug types are available to help lower blood pressure, 
including 
• ACE inhibitors – such as enalapril, lisinopril, perindopril and 
ramipril  
• Angiotensin-2 receptor blockers (ARBs) – such as 
candesartan, irbesartan, losartan, valsartan and olmesartan  
• Calcium channel blockers – such as amlodipine, felodipine 
and nifedipine or diltiazem and verapamil.  
• Diuretics – such as indapamide and bendroflumethiazide  
• Beta-blockers – such as atenolol and bisoprolol  
• aApha-blockers – such as doxazosin  
• Renin inhibitors – such as aliskiren  
• Other diuretics – such as amiloride and spironolactone  
5.1.7.Alternative medicine 
Although diet and exercise are the most appropriate tactics to 
lower blood pressure, some supplements also may help lower it. These 
include: 
• Fiber, such as blond psyllium and wheat bran, Minerals, such 
as magnesium, calcium and potassium, Folic acid, Supplements 
or products that increase nitric oxide or widen blood vessels 
(vasodilators), such as cocoa, coenzyme Q10, L-arginine or 
garlic, Omega-3 fatty acids, found in fatty fish, fish oil 
supplements or flaxseed. 
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5.2.1. Angina Pectoris:  
Angina a symptom of an underlying heart condition. It means 
that the heart is not getting enough blood and as a result, not enough 
oxygen. This decrease of oxygen being delivered to the muscle of the 
heart happens if one or more coronary arteries are narrowed or 
blocked, a condition called atherosclerosis. This type of blockage may 
result in chest pain. And while angina does not usually damage the 
heart, and the pain might only last a few minutes, it is a warning sign 
that should not ignore.  
5.2.2.Different types of angina 
Five different kinds of angina have been identified, with 
the  two most common being stable angina and unstable 
angina. 
Stable angina occurs when the heart has to work harder than 
normal, during exercise, for example. It has a regular pattern, and if 
already know that patient have stable angina, it will be able to predict 
the pattern. Once stop exercising, or take medication (usually 
nitroglycerin) the pain goes away, usually within a few minutes. 
Unstable angina is more serious, and may be a sign that a 
heart attack could happen soon. There is no predictable pattern to 
this kind of angina, it can just as easily occur during exercise as it 
can while are resting. It should always be treated as an emergency. 
People with unstable angina are at increased risk for heart attacks, 
cardiac arrest, or severe cardiac arrhythmias (irregular heartbeat or 
abnormal heart rhythm). Less common kinds of angina include: 
• Variant angina     
• Microvascular angina          
• Atypical angina 
Variant angina is also known as Prinzmetal’s angina. It often 
occurs while someone is resting (usually between midnight and 8:00 
in the morning), and it has no predictable pattern—that is, it is not 
brought on by exercise or emotion. This kind of angina may cause 
severe pain, and is usually the result of a spasm in a coronary artery.  
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Microvascular angina—sometimes referred to as Syndrome X—
occurs when tiny vessels in the heart become narrow and stop 
functioning properly, even if the bigger arteries are not blocked by 
plaque. Usually it is treated with common angina medications  
Atypical angina often doesn’t cause pain, but may feel a vague 
discomfort in chest, experience shortness of breath, feel tired or 
nauseous, have indigestion, or pain in back or neck. Women are more 
likely than men to have feelings of vague chest discomfort. 
 
Causes: 
High blood pressure (for more on high blood pressure, Diabetes, 
Unhealthy cholesterol levels, Smoking, Lack of exercise, Obesity, Too 
much salt in diet, Excessive use of alcohol, Family history of CAD or 
stroke, Being male, Being a postmenopausal woman, Age. 
 
5.2.3.Classification of Drugs 
1. Organic Nitrates and Nitrites 
Nitroglycerin, Isosorbide Dinitrate, Isosorbide mononitrate, Amyl 
nitrite. 
2. Calcium Channel Blockers 
a) Dihydropyridines: Amlodipine, Nicardipine, Nifedipine, 
Nimodipine, Lercanidipine, Nisoldipine, Nitrendipine. 
b) Miscellaneous Drugs: Verapamil, Diltiazem, Bepridil. 
3. Beta-Adrenoceptor Blockers 
Beta 1 and Beta 2 Antagonist: Propranolol, Penbutolol, 
Pindolol, Satolol, Timolol. 
Beta 1 Selective Blockers: Metoprolol, Atenolol, Esmolol, 
Acebutolol, Betaxolol. 
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6. DRUG PROFILE- LERCANIDIPINE HYDROCHLORIDE 
6.1. Description 
Lercanidipine Hydrochloride is an antihypertensive (blood pressure 
lowering) drug. It belongs to the structurally related to the 1,4-
dihydropyridines class of calcium channel blockers, is used alone or with 
an angiotensin-converting enzyme inhibitor, to treat hypertension, 
chronic stable angina pectoris, and Prinzmetal's variant angina. 
Lercanidipine Hydrochloride which work by relaxing and opening 
the blood vessels allowing the blood to circulate more freely around the 
body. This lowers the blood pressure and allows the heart to work more 
efficiently.  
Lercanidipine Hydrochloride isslightly yellow crystalline powder 
and melts at 197 to 201 °C (387 to 394 °F) in crystal form I and 207 to 
211 °C (405 to 412 °F) in crystal form II. It is readily soluble 
in chloroform and methanol, but practically insoluble in water. This 
high lipophilicity (compared to older dihydropyridines) is intentional 
because it causes the substance to bind to lipid membranes, allowing for 
a longer duration of action. 
Fig.No.6: Chemical Structure of Lercanidipine Hydrochloride 
 
6.2. CHEMICAL DATA 
➢ Empirical formula  -  C36H41N3O6 
➢ Molecular weight   - 611.739 g/mol 
CHAPTER-6                                                                                          DRUGPROFILE 
 
J.K.K.NATTRAJA COLLEGE OF PHARMACY Page | 46  
 
➢ CAS Registry No.  - 100427-26-7 
6.2.1.  Systemic (IUPAC) Name: 
5-O-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] 3-
O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-
dicarboxylate 
6.3. Pharmacology: 
6.3.1 Indication 
              For the treatment of Hypertension, management of angina 
pectoris and Raynaud's syndrome. 
6.3.2. Pharmacodynamics 
Lercanidipine, a dihydropyridine calcium-channel blocker, is used 
alone or with an angiotensin-converting enzyme inhibitor, to treat 
hypertension, chronic stable angina pectoris, and Prinzmetal's variant 
angina. Lercanidipine is similar to other peripheral vasodilators. 
Lercanidipine inhibits the influx of extra cellular calcium across the 
myocardial and vascular smooth muscle cell membranes possibly by 
deforming the channel, inhibiting ion-control gating mechanisms, and/or 
interfering with the release of calcium from the sarcoplasmic reticulum. 
The decrease in intracellular calcium inhibits the contractile processes of 
the myocardial smooth muscle cells, causing dilation of the coronary and 
systemic arteries, increased oxygen delivery to the myocardial tissue, 
decreased total peripheral resistance, decreased systemic blood pressure, 
and decreased afterload.  
6.3.3. Mechanism of action 
By deforming the channel, inhibiting ion-control gating mechanisms, 
and/or interfering with the release of calcium from the sarcoplasmic 
reticulum, Lercanidipine inhibits the influx of extracellular calcium 
across the myocardial and vascular smooth muscle cell membranes. The 
decrease in intracellular calcium inhibits the contractile processes of the 
myocardial smooth muscle cells, causing dilation of the coronary and 
systemic arteries, increased oxygen delivery to the myocardial tissue, 
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decreased total peripheral resistance, decreased systemic blood pressure, 
and decreased afterload. 
6.3.4. Pharmacokinetic Parameters: 
Absorption 
The absorption from the gastrointestinal tract was rapid, with T max 
ranging from 0.75 to 1.5. 
Distribution 
The apparent volume of distribution for lercanidipine was in the 
range of 2-2.5 L/kg. 
Metabolism 
When orally administered, lercanidipine HCl undergoes extensive 
biotransformation, and practically no unchanged drug is present in urine 
and feces. The metabolism of lercanidipine involves aromatization of the 
heterocyclic ring, oxidative loss of the N side-chain, and its 
glucuronidation. Other pathways involved include nitro reduction, N,N-
didealkylation, and glucuronidation. Aromatization of the heterocyclic 
ring and hydroxylation of the side-chain, with consequential loss of N - 
methyl -N- (3,3 - diphenyl) propylamine groups, produce a primary 
alcohol, metabolite M8, which undergoes subsequent glucuronidation to 
metabolite M4. Nitro reduction with N,N-didealky-lation leads to the 
formation of an amine metabolite M5. Another metabolite, M7, was 
structurally closely related to M8 but could not be characterized because 
it was present in very small amounts. M7 was conjugated with 
glucuronic acid to produce M5. 
Excretion 
The 93.4 to 96.1% of the administered drug was excreted about 
43.8% in the urine and 50.4% in the feces. No unchanged drug was 
detected in the urine, demonstrating an effectively complete 
biotransformation of lercanidipine before excretion. 
➢ Bio-availability ~10% 
➢ Half life – 8-10  hours 
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➢ Duration of Action ≥ 24 Hours 
➢ Protein binding - > 98% 
Fig.No.7: Evolution of dihydropyridine calcium antagonists 
for improved clinical efficacy and tolerability. Abbreviations: 
GITS, gastrointestinal therapeutic system. 
 
6.3.5.Contraindications 
Like other dihydropyridines, lercanidipine is contraindicated in 
unstable angina pectoris, uncontrolled cardiac failure, shortly after a 
myocardial infarction, and in patients with left ventricular outflow tract 
obstruction. It is also contraindicated during pregnancy and in women 
who may become pregnant, because data regarding safety for the unborn 
are lacking, as well as in patients with severe liver and renal impairment. 
 The drug must not be combined with strong inhibitors of the liver 
enzyme CYP3A4 or with the immunosuppressant drug ciclosporin. 
6.3.6.Overdose 
Overdosing of up to 80 times the usual therapeutic dose has been 
described. Expected symptoms include severe hypotension (low blood 
pressure) and reflex tachycardia. Bradycardia (slow heartbeat) can also 
occur due to blockage of calcium channels in the atrioventricular node of 
the heart. There is no treatment besides monitoring blood pressure and 
heart function. Dialysis is likely ineffective because most of the 
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lercanidipine is bound to blood plasma proteins and lipid membranes of 
cells. 
6.3.7.Interactions 
The substance is metabolised by the liver enzyme CYP3A4. In a 
study, the strong CYP3A4 inhibitor ketoconazole increased the maximal 
blood plasma concentrations of lercanidipine by a factor of eight, and the 
area under the curve by a factor of 15. In another study, ciclosporin 
increased lercanidipine plasma levels threefold when given at the same 
time. Other inhibitors of this enzyme, such as itraconazole, 
erythromycin, and grapefruit juice, are also expected to increase plasma 
concentrations and thus amplify the antihypertensive effect. 
Conversely, CYP3A4 inductors such as carbamazepine, rifampicin, 
and St John's wort probably lower plasma levels and effectiveness of 
lercanidipine. By comparison, amlodipine has a lower potential for 
CYP3A4 mediated interactions. 
Lercanidipine increases plasma levels of ciclosporin and digoxin. 
6.3.8.Side Effects 
Headache, Dizziness, Ankle swelling, Faster heart beat, Awareness 
of the beating or your heart (palpitations), Redness of the face and neck, 
Sleepiness, Feeling and being sick, Rash, Muscle pain, Passing large 
amounts of urine (water) and passing urine more frequently, Tiredness, 
Fainting, Light-headedness, Indigestion, Diarrhoea, Angina (chest pain), 
Pain in the stomach, Allergic reactions, Swelling of the gums, Changes to 
the way the liver functions, Low blood pressure 
 6.3.9.Serious Allergic Reaction: 
• getting a skin rash that may include itchy, red, swollen, blistered or 
peeling skin 
• wheezing 
• tightness in the chest or throat 
• having trouble breathing or talking 
• swelling of the mouth, face, lips, tongue, or throat. 
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7. EXCIPIENTS PROFILE 
7.1. Crospovidone 
Nonproprietary Names 
 BP: Crospovidone  
PhEur: Crospovidone 
USP-NF: Crospovidone 
 
Synonyms: Crospovidonum, crosslinked povidone, Kollidon CL, 
PolyplasdoneXL-10, polyvinylpolypyrrolidone, PVPP, 1-vinyl-2-
pyrrolidinone homopolymer. 
 
Chemical Name and CAS Registry Number: 1-Ethenyl-2-pyrrolidinone 
homopolymer [9003-39-8] 
 
Empirical Formula and Molecular Weight: 
(C6H9NO)     >1 000 000 
 
Structural Formula  
Functional Category 
             Tablet disintegrant. 
 
Description 
 Crospovidone is a white to creamy-white, finely divided, free- 
flowing, practically tasteless, odorless or nearly odorless, hygroscopic 
powder. 
Solubility: 
  Practically insoluble in water and most common organic solvents. 
Applications in Pharmaceutical Formulation or Technology 
• Crospovidone is a water-insoluble tablet disintegrant and 
dissolution agent used at 2–5% concentration in tablets prepared 
by direct compression or wet- and dry-granulation methods.  
• It rapidly exhibits high capillary activity and pronounced hydration 
capacity, with little tendency to form gels.  
• Larger particles provide a faster disintegration than smaller 
particles.  
• Crospovidone can also be used as a solubility enhancer.  
• The drug is adsorbed on to crospovidone in the presence of a 
suitable solvent and the solvent is then evaporated. This technique 
results in faster dissolution rate. 
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7.2. Croscarmellose Sodium 
Nonproprietary Names 
BP: Croscarmellose Sodium 
JP: Croscarmellose Sodium 
PhEur: Croscarmellose Sodium 
USP-NF: Croscarmellose Sodium 
Synonyms: Ac-Di-Sol, crosslinked carboxy methyl cellulose sodium, 
Explocel, modified cellulose gum, Nymcel, ZSX Pharmacel XL, Primellose, 
Solutab, Vivasol. 
Chemical Name and CAS Registry Number:  
Cellulose, carboxymethyl ether, sodium salt, 
crosslinked [74811-65-7]  
Empirical Formula and Molecular Weight :  
The USP 32 describes carboxymethylcellulose 
sodium as the sodium salt of a polycarboxymethyl ether 
of cellulose. 
 
Structural Formula 
 
 
Functional Category: Tablet and capsule disintegrant. 
 
Description: Croscarmellose sodium occurs as an odorless, white or 
grayish white powder. 
Solubility 
Insoluble in water, croscarmellose sodium rapidly swells to 4–8 
times its original volume on contact with water. Practically insoluble in 
acetone, ethanol and toluene. 
Applications in Pharmaceutical Formulation or Technology 
• Croscarmellose sodium is used in oral pharmaceutical 
formulations as a disintegrant for capsules, tablets, and granules.  
• In tablet formulations, croscarmellose sodium may be used in both 
direct-compression and wet-granulation processes.  
• Croscarmellose sodium at concentrations up to 5% w/w may be 
used as a tablet disintegrant, although normally 2% w/w is used 
in tablets prepared by direct compression and 3% w/w in tablets 
prepared by a wet-granulation process. 
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7.3. Sodium Starch Glycolate 
Nonproprietary Names 
BP: Sodium Starch Glycolate 
PhEur: Sodium Starch Glycolate 
USP-NF: Sodium Starch Glycolate 
Synonyms: Carboxymethyl starch, sodium salt, carboxymethylamylum 
natricum, Explosol,  Explotab, starch carboxymethyl ether, sodium salt, 
Tablo,Vivastar P. 
Chemical Name and CAS Registry Number:  
Sodium carboxymethyl starch [9063-38-1] 
Empirical Formula and Molecular Weight :  
The molecular weight is typically 5X105–1106. 
 
Structural Formula 
 
 
Functional Category: Tablet and capsule disintegrant. 
 
Description: Sodium starch glycolate is a white or almost white free-
flowing very hygroscopic powder. When examined under a microscope it 
is seen to consist of granules, irregularly shaped, ovoid or pear-shaped, 
30–100 mm in size, or rounded, 10–35 mm in size, compound granules 
consisting of 2–4 components occur occasionally. The granules show 
considerable swelling in contact with water. 
Solubility 
In water, sodium starch glycolate swells to up to 300 times its 
volume. 
Applications in Pharmaceutical Formulation or Technology 
• Sodium starch glycolate is widely used in oral pharmaceuticals as 
a disintegrant in capsuleand tablet formulations.  
• It is commonly used in tablets prepared by either direct-
compression or wet-granulation processes.  
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• The usual concentration employed in a formulation is between 2% 
and 8%, with the optimum concentration about 4%, although in 
many cases 2% is sufficient.  
• Disintegration occurs by rapid uptake of water followed by rapid 
and enormous swelling. Although the effectiveness of many 
disintegrants is affected by the presence of hydrophobic excipients 
such as lubricants.  
 
7.4. Starch 1500 
Nonproprietary Names 
                              BP, JP, PhEur, USP : starch 
 
Synonyms: partially pregelatinized maize starch. 
Chemical Name and CAS Registry Number:    
Starch [9005-25-8] 
Empirical Formula and Molecular Weight:  (C6H10O5)n where n = 300–
1000. 
 
Structural Formula  
 
 
Functional Category 
Tablet and capsule diluent, tablet and capsule disintegrant, tablet 
Binder, thickening agent. 
 
Description 
Starch 1500 co-processed starch excipient is a mix of globally 
accepted excipients (corn starch and pregelatinized starch) designed for 
use in capsules and tablets. 
 
Applications in Pharmaceutical Formulation or Technology 
• Starch 1500 is a unique pharmaceutical excipient combining 
several properties in a single product act as a binder, disintegrant, 
filler and flow-aid while having lubricant properties.  
• Starch 1500 cuts process and material costs by reducing or 
eliminating polymeric binders, superdisintegrants, high levels of 
lubricants and glidants and manufacturing steps. 
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7.5. Lactose 
Nonproprietary Names 
                              BP           :        Anhydrous Lactose 
                              JP            :        Anhydrous Lactose 
                              PhEur      :        Anhydrous Lactose 
                              USP         :        Anhydrous Lactose 
 
Synonyms: Anhydrous 60M, Anhydrous Direct Tableting (DT),  
Lactopress Anhydrous, Lactopress Anhydrous 250, SuperTab 22AN, 
saccharum lactis. 
Chemical Name and CAS Registry Number:    
O-bD-Galactopyranosyl-(1!4)-b-D-
glucopyranose [63-42-3] 
 
Empirical Formula and Molecular Weight:  
C12H22O11                   342.30 
 
Structural Formula 
 
 
Functional Category 
Directly compressible tablet excipient, 
dry powder inhaler carrier, lyophilization aid, 
tablet and capsule diluent, tablet and capsule 
filler. 
 
Description 
Anhydrous lactose occurs as white to off-white crystalline particles 
or powder. Several different brands of anhydrous lactose are 
commercially available which contain anhydrous β-lactose and 
anhydrous α lactose. Anhydrous lactose typically contains 70–80% 
anhydrous b-lactose and 20–30% anhydrous a-lactose. 
 
Applications in Pharmaceutical Formulation or Technology 
• Anhydrous lactose is widely used in direct compression tableting 
applications, and as a tablet and capsule filler and binder. 
• Anhydrous lactose can be used with moisture-sensitive drugs due 
to its low moisture content. It may also be used in intravenous 
injections. 
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7.6. Mannitol 
Nonproprietary Names 
                              BP           :        Mannitol 
                              JP            :        D-Mannitol 
                              PhEur      :        Mannitol 
                              USP         :        Mannitol 
 
Synonyms: Cordycepic acid, C Pharm Mannidex, E421, Emprove, 
manna sugar. 
 
Chemical Name and CAS Registry Number:   D-Mannitol [69-65-8] 
 
Empirical Formula and Molecular Weight:  C6H14O6 and 182.17 
 
Structural Formula 
 
 
Functional Category 
Diluent, plasticizer, sweetening agent, tablet and 
capsule diluents, therapeutic agent, tonicity agent. 
 
Description 
Mannitol is D-mannitol. It is a hexahydric alcohol related to 
mannose and isomeric with sorbitol. Mannitol occurs as a white, 
odorless, crystalline powder, or free flowing granules. It has a sweet 
taste, approximately as sweet as glucose and half as sweet as sucrose, 
and imparts a cooling sensation in the mouth. Microscopically, it appears 
as orthorhombic needles when crystallized from alcohol. Mannitol shows 
polymorphism. 
 
Applications in Pharmaceutical Formulation or Technology 
• Mannitol is widely used in pharmaceutical formulations and food 
products. In pharmaceutical preparations it is primarily used as a 
diluent (10–90% w/w) in tablet formulations. 
• Mannitol may be used in direct-compression tablet applications for 
which the granular and spray-dried forms are available. 
• Mannitol is commonly used as an excipient in the manufacture of 
chewable tablet. 
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• In lyophilized preparations, mannitol (20–90% w/w) has been 
included as a carrier to produce a stiff, homogeneous cake that 
improves the appearance of the lyophilized plug in a vial. A 
pyrogen-free form is available specifically for this use. 
• Mannitol has also been used to prevent thickening in aqueous 
antacid suspensions of aluminum hydroxide (<7% w/v). 
 
7.7. Magnesium Stearate 
 
Nonproprietary Names 
BP: Magnesium Stearate 
JP: Magnesium Stearate 
PhEur: Magnesium Stearate 
USP-NF: Magnesium Stearate 
 
Synonyms: Dibasic magnesium stearate, magnesium distearate, 
magnesia  stearas. 
 
Chemical Name and CAS Registry Number: Octa decanoic acid 
magnesium salt and [557-04-0] 
 
Empirical Formula and Molecular Weight:  C36H70MgO4 and591.24 
 
Structural Formula: [CH3(CH2)16COO]2Mg 
 
 
 
Functional Category: Tablet and capsule lubricant 
 
Description 
Magnesium stearate as a compound of magnesium with a mixture 
of solid organic acids that consists chiefly of variable proportions of 
magnesium stearate and magnesium palmitate. (C32H62MgO4). 
Magnesium stearate is a very fine, light white, precipitated or 
milled, impalpable powder of low bulk density, having a faint odor of 
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stearic acid and a characteristic taste. The powder is greasy to the touch 
and readily adheres to the skin. 
 
Applications in Pharmaceutical Formulation or Technology 
Magnesium stearate is widely used in cosmetics, foods, and 
pharmaceutical formulations. It is primarily used as a lubricant in 
capsule and tablet manufacture at concentrations between 0.25% and 
5.0% w/w. It is also used in barrier creams. 
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7.8. Aspartame 
Nonproprietary Names 
BP: Aspartame 
PhEur: Aspartame 
USP-NF: Aspartame 
Synonyms: 3-amino-N-(a-methoxycarbonylphenethyl)-succinamic acid, 
APM, aspartamum, aspartyl phenylamine methyl ester, Canderel, E951, 
Equal, methyl N-L-a-aspartyl-L-phenylalaninate, NatraTaste,  
NutraSweet, Pal Sweet, Pal Sweet Diet. 
 
Chemical Name and CAS Registry Number: N-L-a-Aspartyl-L-
phenylalanine 1-methyl ester [22839-47-0] 
Empirical Formula and Molecular Weight:  C14H18N2O5  294.30 
 
Structural Formula:  
 
 
 
Functional Category: Sweetening agent. 
 
Description: Aspartame occurs as an off white, almost odorless 
crystalline powder with an intensely sweet taste. 
Applications in Pharmaceutical Formulation or Technology 
Aspartame is used as an intense sweetening agent in beverage 
products, food products, and table-top sweeteners, and in 
pharmaceutical preparations including tablets, powder mixes, and 
vitamin preparations. The approximate sweetening power is 180–200 
times that of sucrose. 
Unlike some other intense sweeteners, aspartame is metabolized in 
the body and consequently has some nutritive value: 1 g provides 
approximately 17 kJ (4 kcal).  
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8. MATERIALS AND EQUIPEMENTS 
 8.1. MATERIALS USED: 
Table. No. 4: Materials Used 
S.No Materials Suppliers / Manufacturer 
1 Crosspovidone / PVP 
Disintegrant 
Chemico Glass & Scientific 
Company, Erode. 
2 Croscarmellose sodium (CCS) Loba Chemie Pvt Ltd 
3 Sodium Starch Glycolate (SSG) Nice chemicals 
4 Starch 1500 Nice chemicals 
5 Lactose Loba Chemie Pvt Ltd 
6 Mannitol 
 
Nice chemicals 
7 Magnesium Stearate Loba Chemie Pvt Ltd 
8 Sucralose Nice chemicals 
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8.2.  INSTRUMENTS USED 
Table. No. 5: Instruments Used 
S.No Equipment 
Manufacturer 
 
1 Digital Balance Shimadzu Analytical 
2 Sieves Indicot (India) 
3 Tapped Density Tester Electrolab 
4 Mechanical Stirrer Remi Motors, Mumbai 
5 UV-Visible Spectrophotometer LAB INDIA UV 3000+ 
6 Dissolution Test Apparatus 
Labindia Analytical 
Instruments Pvt Ltd. 
Mumbai , Model-
DISSO 2000 
7 
Temperature controller(hot air 
oven) 
ROLEX 
8 FTIR BRUKER HTS-XT 
9 Compression machine Proton Mini Press 
10 Vernier Calipers Indicot 
11 
Disintegration Test 
Apparatus,USP 
ROLEX 
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9. PREFORMULATION 
 Preformulation testing is first step in the rational development of 
dosage forms of a drug substance. It can be defined as – “as investigation 
of physical and chemical properties of a drug substance alone and when 
combined with excipients”. The overall objective of preformulation testing 
is to generate information useful to the formulation in developing stable 
and bioavailable dosage forms that can be mass produced.  The 
preformulation should start at the point after biological screening, when 
a decision is made for further development of compound in clinical trials.  
The preformulationstudies should consider the following before going 
through the formal program which includes: 
• Available physicochemical data (including chemical structure and 
different salts available). 
• Anticipated dose 
• Supply situation and development schedule. 
• Availability of stability , assay. 
• Nature of information the formulator should have or would like to 
have. 
The following preformulation studies were performed for the 
obtained sample of drug.   
 
9.1. Organoleptic properties 
9.1.1. Color and nature 
Transferred small quantity of the sample on a white piece of paper, 
spreaded the powder and examined visually. 
Lercanidipine Hydrochloride is a white citrine-yellow crystalline 
powder. 
 
 9.1.2. Particle Size , Shape and Surface Area 
Various physical and chemical properties of drug substances are 
affected by their particle  size distribution and shapes. Size also plays a 
role  inthe homogeneity of final tablet.  When large differences in size 
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exist between the API and excipientsm mutual sieving (demixing) effects 
can occur making through mixing difficult on, it attained, difficult to 
maintain during the subsequent processing steps. 
If the material become too fine, then undesirable properties such 
as electrostatin force effects and other surface active properties causing 
undue stickiness and lack of flowability manifest.  It is probably safest to 
grind most drugs having particles that are approx 100µm in diameter. 
 
Table. No. 6: General Techniques For Determining Particle Size 
Techniques Particle size( µm) 
Microscopic 1-100 
Sieve >50 
Sedimentation >1 
Eutriation 1-50 
Centrifugal <50 
Permeability >1 
Light Scattering 0.5-50 
 
9.2. Physical characteristics: 
9.2.1.Flow properties:  
  The flow properties of powders are critical for an efficient 
tableting operation.  A good flow of powder or granulation to be 
compressed is necessary to assure efficient missing and acceptable 
weight uniformity for the compressed tablets.  If a drug is identified at 
the pre formulation stage to be “poorly flowable”, the problem can be 
solved by selecting appropriate excipients.  In some cases, drug powders 
may have to be pre-compressed or granulated to improve their flow 
properties.  During pre formulation evaluation of drug substance, 
therefore, its flowability characteristic should be studied, especially when 
the anticipated dose of the drug is large. 
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9.2.2.Angle of Repose: 
Angle of repose is defined as the maximum angle possible between 
the surface of a pile of the powder and the horizontal plane. 
 
Procedure:  
 A funnel was kept vertically in a stand at a specified height above a 
graph paper placed on a horizontal surface.  The funnel bottom is closed 
and 10 gm of sample powder is filled in funnel.  Then funnel was opened 
to release the powder on the paper to form a smooth conical heap, is 
found by measuring in different direction.  The height of the heap was 
measured by using scale.  The values of angle of repose are calculated by 
using the following formula: 
tanθ = h/r 
 
 
Where,  θ – angle of repose 
h- Height of the heap  
 r - Radius of the heap  
 
              Table. No. 7: Angle of repose limits. 
Angel of 
repose 
Flowability 
<25 Excellent 
25-30 Good 
30-40 Passable 
>40 Very poor 
 The results shown in results and discussion. 
 
9.2.3.Bulk density 
 Bulk density is the ratio of mass of powder to the bulk volume. 
Bulk density largely depends on particle shape, as the particles become 
 = tan -1 (h/r) 
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more spherical in shape, bulk density is increase. In addition as granules 
size increase, bulk density decrease. 
 Bulk density is determined by measuring the volume of a known 
mass of powder sample that has been passed through a screen into a 
graduated cylinder. 
Procedure: 
 A known quantity of powder was poured into the measuring 
cylinder carefully level the powder with out compacting, if necessary and 
read the unsettled apparent volume. Calculate the bulk density, in gm 
per ml, by the formula 
                                             (ρb) = m / Vb. 
Where,  ρb =Bulk Density  
  m = mass of powder 
  Vb = initial / bulk volume 
The results shown in results and discussion 
 Tapped density: 
 Tapped density is the ratio of mass of powder to the tapped 
volume. 
Procedure: 
 A quantity of 5g of the powder (W) from each formula was 
introduced into a 25 ml measuring cylinder. After the initial volume 
was observed, the cylinder was allowed to fall under its own weight 
onto a hard surface from the height of 2.5 cm at 2 sec intervals. The 
tapping was continued until no further change in volume was noted. 
Calculate the tapped density, in gm per ml, by the formula: 
(ρt)= m/Vt 
Where,  ρt =Tapped Density 
  m = mass of powder 
  Vt= final / tapped volume 
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9.2.4.Measurement of Powder Compressibility:  
 The compressibility Index are measures of the propensity of a 
powder to be compressed. As such, they are measures of the relative 
importance of inter particulate interactions. In a free flowing powder, 
such interactions are generally less and tapped densities will be closer in 
value. For poorer flowing materials, there are frequently greater inter 
particle interactions, and a greater difference between bulk and tapped 
densities will be observed. These differences are reflected in the 
compressibility Index Calculated by the formula, 
            Tapped density - Initial bulk density 
% Compressibility   =   ————————————————— x 100 
      (Carr’s index)                             Tapped density    
 
Table. No: 8. Flow properties and corresponding Carr’s Index values 
Excellent <10 
Good 11 – 15 
Fair 16 – 20 
Possible 21 – 25 
Poor 26 – 31 
Very poor 32 – 37 
Very very poor >38 
 The results are shown in results and discussion. 
 
 
9.2.5.Hausner Ratio: 
 It is the ratio of volume of tapped volume or tapped density to bulk 
density.  Hausner Ratio =  Vb/Vt or ρt /ρb. 
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Table. No: 9. Flow Properties and Corresponding Hausner’s ratio 
Excellent 1.00 – 1.11 
Good 1.1 – 1.18 
Fair 1.19 – 1.25 
Possible 1.26 -1.34 
Very poor 1.35 -1.45 
Very very poor >1.60 
 
9.2.6. Melting point: 
It is one of the parameters to judge the purity of crude drugs.  In case of 
pure chemicals, melting points are very sharp and constant.   
Procedure: 
 A small quantity of powder was placed into a fusion tube.  That 
tube is placed in the melting point apparatus containing castor oil.  The 
temperature of the castor oil was gradual increased automatically and 
read the temperature at which powder started to melt and the 
temperature when all the powder gets melted. The results shown in 
results and discussion. 
 
9.2.7. Solution properties: 
Solubility: 
A semi quantitative determination of the solubility was made by 
adding solvent in small incremental amount to a test tube containing 
fixed quantity of solute or vice versa.  After each addition, the system is 
vigorously shaken and examined visually for any undissolved solute 
particles.   The solubility are expressed in terms of ratio of solute and 
solvent. The results are shown in table.9. 
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9.2.8  Identification of drug and compatibility study: 
9.2.8 a) Identification of drug By FT-IR: 
  The drug can be identified by using FT-IR. 
9.2.8 b) By Physical observation 
It was determined as per procedure given in method section. The 
following table illustrated the result. 
Table. No:10. Physical Compatibility Studies 
Test Observations Inference 
Physical 
compatibility 
No change of 
color 
These materials are 
compatible for formulations. 
 
9.2.8 c) Procedure By FT-IR Studies 
The IR spectrums of the Lercanidipine Hydrochloride with exipients 
were taken by preparing dispersion in dry potassium bromide under dry 
condition. Superimposed these spectra. The transmission minima 
(absorption maxima) in the spectra obtained with the sample 
corresponded in position and relative size to those in the spectrum 
obtained with the standards. 
 
9.3. UV SPECTROSCOPIC METHOD FOR ANALYSIS OF 
LERCANIDIPINE HYDROCHLORIDE 
9.3.1.CALIBRATION CURVE OF LERCANIDIPINE HYDROCHLORIDE: 
Measured the absorbance of the above prepared standard 
solutions at 238 nm. Plotted a graph of concentration (in g/ml) on X 
axis and absorbance (in nm) on Y axis  
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TableNo: 11. Caliberation curve for Lercanidipine Hydrochloride 
S. No. 
Concentration 
(g/ml) 
Absorbance (nm) 
1 0 0 
2 5 0.178 
3 10 0.336 
4 15 0.489 
5 20 0.644 
6 25 0.807 
Slope 0.0326 
R2 0.9998 
 
Figure No: 8 : Caliberation Curve of Lercanidipine Hydrochloride 
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10. FORMULATION AND DEVELOPMENT OF LERCANIDIPINE 
HYDROCHLORIDE  IMMEDIATE RELEASE TABLETS 
 
Table. No: 12. FORMULATION F1-F8 
INGREDIENTS(in mg) 
FORMULATION BATCHES 
F1 F2 F3 F4 F5 F6 F7 F8 
Lercanidipine Hydrochloride 10 10 10 10 10 10 10 10 
Sodium Starch Glycolate (SSG) 3 6 9 12 - - - - 
Croscarmellose sodium (CCS) - - - - 3 6 9 12 
Crospovidone / PVP - - - - - - - - 
Starch 1500 - - - - - - - - 
Lactose 50 50 50 50 50 50 50 50 
Mannitol  63 60 57 54 63 60 57 54 
Magnesium Stearate 1 1 1 1 1 1 1 1 
Sucralose 3 3 3 3 3 3 3 3 
Average Weight 130 130 130 130 130 130 130 130 
 
 
 
 
 
 
CHAPTER-10                                                                                 FORMULATION 
 
J.K.K.NATTRAJA COLLEGE OF PHARMACY Page 70 
 
Table. No: 13. FORMULATION F9-F16 
INGREDIENTS(in mg) 
FORMULATION BATCHES 
F9 F10 F11 F12 F13 F14 F15 F16 
Lercanidipine Hydrochloride 10 10 10 10 10 10 10 10 
Sodium Starch Glycolate (SSG) - - - - - - - - 
Croscarmellose sodium (CCS) - - - - - - - - 
Crospovidone / PVP 3 6 9 12 - - - - 
Starch 1500 - - - - 3 6 9 12 
Lactose 50 50 50 50 50 50 50 50 
Mannitol  63 60 57 54 63 60 57 54 
Magnesium Stearate 1 1 1 1 1 1 1 1 
Sucralose 3 3 3 3 3 3 3 3 
Average Weight 130 130 130 130 130 130 130 130 
 
Procedure: 
  All the ingredients were weighed and mixed well. Then it is tableted by direct 
compression method - proton Mini Press 
CHAPTER 11 
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11. EVALUATION 
11.1. PRE-COMPRESSION PARAMETERS: 
A) Angle of repose: 
      Angle of repose is defined as the maximum angle possible between 
the surface of a pile of the powder and the horizontal plane. 
5 grams of the sample was taken in a funnel fixed in a holder (6 
cm) above the surface at an appropriate height and a graph of sheet was 
placed below the funnel. The sample was passed through the funnel 
slowly. The height of the powder heap formed was measured. The 
circumference of the heap formed was drawn with a pencil on the graph 
paper. The radius was measured and the angle of repose was determined 
using the above formula. This was repeated five times for a sample. 
Table. No: 14. Flow properties and corresponding Angle of Repose 
Flow property Angle of Repose (Degree) 
Excellent 25-30 
Good 31-35 
Fair-aid not needed 36-40 
Passable- may hang up 41-45 
Poor- must agitate, vibrate 46-55 
Very poor 56-65 
Very, very poor > 66 
 
 
 
Where, 
h = height, 
r = radius, 
 = Angle of repose. 
The results are given in results and discussion. 
 
 = tan -1 (h/r) 
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B) Determination of bulk density and tapped density: 
A quantity of 5g of the powder (W) from each formula was 
introduced into a 25 ml measuring cylinder. After the initial volume was 
observed, the cylinder was allowed to fall under its own weight onto a 
hard surface from the height of 2.5 cm at 2 sec intervals. The tapping 
was continued until no further change in volume was noted. The bulk 
density, and tapped density were calculated using the following formulas  
 
 
Where, 
 m = mass of the powder, 
Vb = initial or bulk volume, 
Vt = final or tapped volume. 
 The results are shown in results and discussion. 
C) Measurement of  Hausner ratio and Carr’s Index 
a. Hausner’s Ration: 
          Hausner’s ratio indicates the flow properties of powder and 
measured by the ratio of tapped density to bulk density. Hausner’s ratio 
was determined by the given formula: 
Hausner Ratio = Vb/Vt 
Where, 
Vb = initial or bulk volume 
Vt = final or tapped volume 
The results are shown in results and discussion.  
 
 
 
 
 
 
 
Bulk density(ρb)= m / Vb 
  Tapped density(ρt)= m/Vt 
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Table. No: 15. Scale of flowability 
Compressibility index (%) Flow character Hausner Ratio 
≤ 10 Excellent 1.10-1.11 
11-15 Good 1.12-1.18 
16-20 Fair 1.19-1.25 
21-25 Passable 1.26-1.34 
26-31 Poor 1.35-1.45 
32-37 Very poor 1.46-1.59 
>38 Very, very poor >1.60 
 
b. Carr’s Index/Compressibility Index:  
 Compressibility is the ability of powder to decrease in volume 
under pressure using bulk density and tapped density the percentage 
compressibility of powder were determined, which is given as carr’s 
compressibility index. It is indirectly related to the relative flow rate. 
Carr’s compressibility index was determined by the given formula 
                               Tapped density - Initial bulk density 
% Compressibility   =   ————————————————— x 100 
                    (Carr’s index)                             Tapped density 
 
The results shown in results and discussion. 
 
11.2.EVALUATION OF  LERCANIDIPINE HYDROCHLORIDE TABLETS: 
a. Weight Variation Test: 
  The tablet of one particular batch should have uniformity in 
weight.  If any weight variation is found, it should fall within the 
prescribed limits. According to USP maximum % deviation allowed are as 
follows :- 
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Table. No: 16.Weight Variation Test. 
Average weight of 
tablets(mg) 
Maximum % difference 
allowed 
130mg or less ±10% 
130-324mg ±7.5% 
Above 324mg ±5% 
 
  A sample of 20 tablets is selected randomly from a particular 
batch and weighed individually and collectively. The average weight of 
the tablets is calculated. The individual weights are then compared with 
average weight. The weights of not more than two of the tablets should 
not differ and calculate the average weight by more than the prescribed 
limit and no tablet should differ by more than the double the limits.  
                                      Tablet weight-Average weight 
% Deviation   =   ————————————————— x 100 
                   Tablet weight 
The results shown in results and discussion 
 
b. Friability Test: 
20 tablets were weighed and subjected to rotate on friability test 
apparatus. The drum rotated at a speed of 25 rpm for 4 minutes, then 
dedusted and reweighed the tablets. Percentage friability was calculated 
by the following formula.  
 
 
Where, 
 Wo = Initial weight,  
  W   = Final weight.  
 Percentage friability of tablets less than 1% is considered 
acceptable. The results shown in results and discussion. 
 
 
Percentage of Friability (%F)=100 (1-w/w0) 
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c. Hardness Test: 
 Hardness of a tablet determines its tensile strength.  It must be 
such that the tablets withstand the shock of handling, packing, and 
shipping.  It is measured in terms of load/pressure required to crush it 
when placed on its edge.  Generally, two types of hardness testers are 
used to determine the hardness. 
Monsanto Hardness Tester: 
  It consists of a barrel containing a compressible spring held 
between two plungers.  The spring can be compressed by moving the 
knob forward.  The tablet to be tested held between a fixed and moving 
plunger and reading of the indicator is adjusted to zero.  The force 
applied to the edge of the tablet is gradually increased by moving the 
screw know forward until the breaks. The reading is noted from the scale 
which indicates the pressure required in kg or lb/cm2to break the tablet.  
Hardness of 4kg/cm2 is considered to be minimum requirement. 
Pfizer Tablet Hardness Tester: 
 This is slightly improved instrument used for determing the 
hardness of tablet.  It works on the principle of plier.  Pressure gauze is 
fitted on one arm of the tester.  The tablet to be tested is put vertically in 
between the jaws which are pressed with hand until the tablet breaks.  
The reading can be noted from the indicator of the pressure gauze in 
terms of kg or lbs. 
 The hardness of  a sample batch of Escitaloparam  tablets was 
carried out by using Monsanto type hardness tester. The hardness of the 
tablet kg / cm² was measured.  
The results are shown in results and discussion. 
d. Thickness Test:  
Control of physical dimension of the tablets such as sizes and 
thickness is essential for consumer acceptance and to maintain tablet to 
tablet uniformity.  Manufacturers set the limits on the thickness of the 
tablets of their products in order to avoid any problems during automatic 
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counting and packing. If the thickness of the tablet goes beyond a certain 
limit, it may block the channels of the machines. Hence there should be 
in-process control to maintain the thickness of the tablets.  The 
dimensional specifications were measured using vernier calipers.  
Six tablets from each batch were tested and average values were 
calculated.The thickness of the tablet is mostly related to the tablet 
hardness can be uses as initial control parameter. 
 The results are shown in results and discussion.  
e. Diameter and Shape:   
           The diameter and shape of the tablets are determined by the dies 
and punches used for the compression.  Less concave the punches, the 
more flat will be the tablets.  Conversely, the more concave the punches, 
more convex would be the resulting tablets.  Similarly, punches having 
raised impressions will produce recessed impressions on the tablets.  
Whereas punches having recessed impression, will produce raised 
impressions on the tablet surface.  Therefore, proper selection of 
punches and dies should be done so as to produce tablets will desired 
diameter and shape. 
f. Drug content: 
Weigh and powdered 10 tablets in a mortar. From this powder 
equivalent to 100mg of Lercanidipine Hydrochloride  was taken in a 
100ml volumetric flask to this water was added and then the solution 
was subjected to sonication for about 10min’s for complete solubilization 
of drug and the solution was made up to the mark with water filtered the 
drug content was estimated by measuring the absorbance at 244 nm by 
using UV-Visible spectrophotometer. 
 
g. Disintegration Time: 
The test is performed invitro to determine the time in which a tablet 
disintegrates in the water at the 37±2°C. The apparatus which is used to 
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simulate all the conditions of mouth, for the determination of 
disintegration time is called as Disintegration Time. 
It consist of two hot plates with housing for beakers, 
thermostatically controlled heaters to maintain the temperature, two 
baskets each having provision for fixing 6 glass or plastic tubes provided 
with guided discs and stainless wire mesh.  Each unit is suitable for 
performing two tests at a time. 
The glass or plastic tubes are open at one end and fitted with sieve 
No. 10 mesh at the other end. The tubes are suspended in bath 
containing water or suitable liquid which is maintained through a 
distance of 75mm, the volume of the liquid and the distance of movement 
is adjusted in such a way that the highest point, the sieve should break 
the surface of the liquid.  
six tablets are placed in each of the six tubes along with a guided 
plastic disc over the tablets tube and the assembly was suspended into 
the 1000ml beaker containing Water maintained at 37±2°C and operated 
the apparatus for 15 minutes. The tubes are allowed to move up and 
down as per the specification discussed above and the disintegration 
time is noted when all the tablets particles have passed through the 
sieve.  The disintegration time should comply with official time unless 
otherwise in the monographs. The assembly was removed from the liquid 
and the tablets were observed. If one or two tablets fail to disintegrate 
completely, repeat the test on 12 additional tablets. The requirement is 
met if not less than 16 of the total of 18 tablets tested are disintegrated. 
h. Wetting time and water absorption ratio:  
Wetting time of dosage form is related to with the contact angle. 
Lower wetting time implies a quicker disintegration of the tablet. 
Wetting time: 
It is closely related to the inner structure of the tablets and to the 
hydrophilicity of the excipients. To measure wetting time, five circular 
tissue papers of 10cm diameter are placed in a petridish with a 10cm 
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diameter. 10ml of water containing eosin, a water soluble dye, is added 
to petridish. A tablet is carefully placed on the surface of the tissue 
paper. The time required for water to reach upper surface of the tablet is 
noted as a wetting time. 
Water absorption ratio:   
A piece of tissue paper folded twice was placed in a small Petri dish 
containing 6 ml of water. A tablet was put on the paper & the time 
required for complete wetting was measured. The wetted tablet was then 
weighed. The water absorption ratio, R can be the determined according 
to the following equation; 
R = 100 (Wa-Wb) / Wb 
Where,  
Wb; The weight of the tablet before keeping in the petridish. 
Wa; The wetted tablet from the petridish is taken and reweighed. 
i.  Dissolution: 
Dissolution Rate: 
Dissolution rate is defined as the amount of solute dissolved in a given 
solvent per unit time under standard conditions of temperature, pH, 
solvent composition and constant solid surface area. The developed 
dissolution test can serve also a routine control mechanism to assure the 
proper dissolution characteristics, as well as the uniformity of regular 
production. 
Measurement of the Intrinsic Dissolution Rate: 
• This measurement is extremely important input factor during the 
initial drug screening and formulation development programs. 
• Measurement over the entire physiological pH range can be very 
useful in predicting whether the absorption of moderately or poorly 
soluble drugs is dissolution rate limited. 
• Such information is essential in order to develop a suitable dosage 
form that is free from bioavailability problems. 
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• The information also is very useful for improving existing 
formulations that have demonstrated bioavailability problems. 
• It is important to point out while the intrinsic dissolution rate data is 
very useful in characterizing the solubility behavior of drug 
substance, it is of little value in describing the characteristics of the 
pharmaceutical forms. 
Dissolution Apparatus of Immediate Release Lercanidipine 
Hydrochloride  tablets: 
invitro dissolution of  Lercanidipine Hydrochloride  was studied in 
USP dissolution apparatus (Electrolab) employing a Basket stirrer. 900 
ml Water was used as dissolution medium at 50 rpm. The temperature of 
37 ± 0.5 °C was maintained throughout the experiment. Complex 
equivalent to mg of Lercanidipine Hydrochloride  was used in each test.   
5 ml of sample of dissolution medium were withdrawn by means of 
syringe fitted with pre-filter at known intervals of time and analyzed for 
drug release by measuring the absorbance at 238 nm after suitable 
dilution with 6.8 pH phosphate buffer. The volume withdrawn at each 
time interval was replaced with fresh quantity of dissolution medium. 
The amount of Lercanidipine Hydrochloride  released was calculated and 
plotted against time and compared with marketed drug was studied. 
Dissolution Study 
In-vitro release profile: 
 Medium    : Water 900ml. 
 Apparatus : USP II (Paddle) 
 Speed        : 50 rpm 
 Time        : 30 minutes 
 Temperature  : 37 0C ± 0.5 0C 
 λ Max   : 238 nm  
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Perform the test on six tablets place one tablet in each dissolution vessel 
containing 900 ml of 6.8 pH Phosphate buffer maintained at 37 0C ± 0.5 
0C. At specified time withdrawn required amount of sample and replace 
the same amount with (maintain sink condition), then absorbance was 
taken and calculate percentage release.  
               Absorbance X 900 X Dilution 
% Purity   =   ————————————— x 100 
              Slope X 1000 X label claim 
 The results are given in results & discussion. 
j. Stability studies: 
 The optimized tablets were packed in amber-colored bottle, which 
was tightly plugged with cotton and capped. It was then stored at 40°C / 
75% RH for 8 weeks. The tablets were evaluated for hardness, drug 
content and dissolution study and compared with tablets evaluated 
immediately after manufacturing. 
CHAPTER 12 
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12. RESULT AND DISCUSSION 
12.1.Pre formulation Studies: 
Organoleptic properties: 
 These tests were performed as per procedure. The results are illustrated 
in following table.  
Table. No. 17:  Organoleptic Properties 
Test Specification / limits Observations 
Color  White color white powder 
Odour Odourless Odourless 
The result complies as per specification. 
Angle of repose : 
 It was determined as per procedure given in material and method part. 
The results are, 
Table. No.18: Flow properties  
Material Angle of repose 
Lercanidipine Hydrochloride   29o.27” 
The result shows that drug having poor flow. 
Bulk density and tapped density: 
 It was determined as per procedure given in material and method part. 
The results are, 
                                                               Table. No.19: Density 
Material 
Bulk Density 
(gm/ml) 
Tapped density 
(gm/ml) 
Lercanidipine 
Hydrochloride 
0.28 0.23 
Powder compressibility: 
 It was determined as per procedure given in material and method part. 
The results are, 
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Table. No.20: Powder Compressibility  
Material Compressibility 
index 
Hausner ratio 
Lercanidipine 
Hydrochloride 
18.92% 1.19 
 
Melting point: 
 It was determined as per procedure given in material and method part. 
The results are, 
Table. No. 21: Melting point 
Material Melting point range Result 
Lercanidipine 
Hydrochloride   
185-188 °C Complies 
The result indicates that the Lercanidipine Hydrochloride  drug was pure 
one.  
SOLUTION PROPERTIES: 
Solubility: 
 It was determined as per procedure given in 9.4.2 in material and 
method part. The following table 17 illustrated the result. 
Table. No.22: Solubility 
Test Specification Result 
Solubility 
water: 9.3 mg/100 ml 
ethanol 95%: 4.7 g/lOOml 
ethanol 99%: 4.7 g/lOOml 
dimethylformamide: >lo0 g/100 ml 
Complies 
The result complies as per specification. 
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Drug - Excipient Compatibility Studies 
A) Physical Observation: 
There are no such changes in the physical observation after mixing 
of ingredients. 
B) Drug Identification by FTIR: 
The graph is compared with the standard FTIR graph given in 
pharmacopoeia or prescribed standards and confirmed through the 
corresponding peaks. 
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PRECOMPRESSION PARAMETERS: 
Table. No. 23: EVALUATIONS OF GRANULES 
Batc
h. 
N0. 
Angle of 
Repose(0) 
Bulk 
Density(g/
ml) 
Tapped 
bulk 
density(g/
ml) 
Carr’s index 
(%) 
Hausner’s  
Ratio 
F1 24°31' 0.518 0.622 14.33 1.13 
F2 23°12' 0.533 0.634 13.28 1.12 
F3 24°27' 0.540 0.628 14.76 1.14 
F4 25°34' 0.521 0.626 13.24 1.16 
F5 26°.52' 0.533 0.633 13.37 1.13 
F6 25°.71' 0.541 0.631 12.59 1.12 
F7 26°.69' 0.532 0.629 12.47 1.18 
F8 26°.14' 0.538 0.630 11.43 1.17 
F9 25°.33' 0.522 0.629 13.22 1.12 
F10 26°.87' 0.524 0.636 13.71 1.11 
F11 24°.32' 0.533 0.638 13.37 1.12 
F12 25°.29' 0.538 0.634 13.22 1.12 
F13 23°.09' 0.545 0.623 12.85 1.15 
F14 24°.67' 0.539 0.625 13.26 1.14 
F15 24°.31' 0.536 0.619 12.41 1.13 
F16 24°.22' 0.537 0.612 12.49 1.14 
Discussion: 
The angle of repose for the formulated blend F1-F16 was found to be in 
the range 230.09' to 260.87' shows good flow property.  
Compressibility index for the formulations F1-F16 found between 
11.43% to 14.76% indicating  the powder blend has the required flow property 
for compression.  
Hausner’s Ratio for the formulations F1-F16 found between 1.11 to 1.18 
indicating  the powder blend has the required flow property for compression.  
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EVALUATION OF LERCANIDIPINE HYDROCHLORIDE  TABLETS: 
Table. No: 24.WEIGHT VARIATION AND FRIABILITY: 
Batch. 
No 
Weight 
Variation (%) 
Friability (%) 
F1 130±1.22 0.61 
F2 131±1.38 0.50 
F3 129±1.34 0.59 
F4 130±1.29 0.63 
F5 130±1.41 0.55 
F6 131±1.28 0.66 
F7 132±1.26 0.51 
F8 131±1.24 0.68 
F9 129±1.46 0.69 
F10 130±1.32 0.62 
F11 129±1.26 0.51 
F12 129±1.29 0.55 
F13 131±1.02 0.64 
F14 130±1.25 0.50 
F15 131±1.24 0.63 
F16 130±1.32 0.54 
 
Discussion:  
The weight variation of the tablet in the range of ± 1.02 % to ± 1.46 % ( 
below 5%) complying with pharmacopoeial specification. 
The friability of the tablet in the range of 0.50 % to 0.69% (below 1%) 
complying with pharmacopoeial specifications. 
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Table. No: 25. Thickness, Hardness and Disintegration Time: 
Batch. 
No 
Thickness 
(mm) 
Hardness 
(Kg/cm2) 
F1 2.03±0.2 2.22 
F2 2.01±0.2 2.33 
F3 2.02±0.2 2.26 
F4 2.03±0.2 2.23 
F5 2.02±0.1 2.33 
F6 2.03±0.3 2.25 
F7 2.02±0.1 2.31 
F8 2.02±0.2 2.26 
F9 2.01±0.1 2.27 
F10 2.02±0.2 2.25 
F11 2.02±0.2 2.19 
F12 2.01±0.3 2.24 
F13 2.03±0.2 2.29 
F14 2.02±0.3 2.33 
F15 2.01±0.1 2.34 
F16 2.02±0.2 2.27 
 
Discussion: 
The thickness of the formulations from F1- F16 was found to be in the 
range of 2.01±0.1 to 2.03±0.3 and hardness of the formulated tablets was 
found to 2.19 to 2.34 indicating a satisfactory mechanical strength.  
 
 
 
 
 
 
 
 
CHAPTER- 12                                                                RESULT AND DISCUSSION 
 
J.K.K.NATTRAJA COLEGE OF PHARMACY Page 90 
 
Table. No: 26. Wetting Time and Disintegration Time: 
Batch. 
No 
Wetting Time 
(Sec) 
DISINTEGRATION 
TIME (seconds) 
F1 90 110 
F2 85 102 
F3 73 93 
F4 69 85 
F5 103 160 
F6 98 138 
F7 83 115 
F8 73 105 
F9 32 63 
F10 29 55 
F11 25 42 
F12 19 35 
F13 178 223 
F14 154 201 
F15 133 192 
F16 111 150 
 
Discussion: 
The Wetting time of the formulations from F1- F16 was found to be in the 
range of                    19-178 seconds. Lower wetting time implies a quicker 
disintegration of the tablet. F12 shows very lower wetting time it reflects in 
faster DT.  
Water absorption ration is around 67% shows for the formulation F8. 
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Table. No:27. Cumulative % Release of Lercanidipine Hydrochloride 
Mouth Dissolving Tablets F1-F4 
 
Fig. No:15. Cumulative % Release of Lercanidipine Hydrochloride Mouth 
Dissolving Tablets F1-F4 
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Time (mts) 
% Drug Release of Formulations 
F1 F2 F3 F4 
0 0 0 0 0 
1 31.03 36.34 39.22 41.13 
2 43.47 51.07 54.61 56.22 
4 49.04 65.18 69.13 70.11 
6 58.75 72.18 75.96 79.74 
8 66.21 89.72 86.27 88.33 
10 73.66 94.27 97.43 96.24 
12 88.20 99.42 99.26 99.31 
15 98.45 --- --- --- 
17 --- --- --- --- 
CHAPTER- 12                                                                RESULT AND DISCUSSION 
 
J.K.K.NATTRAJA COLEGE OF PHARMACY Page 92 
 
Table. No:28. Cumulative % Release of Lercanidipine Hydrochloride 
Mouth Dissolving Tablets F5-F8 
 
Fig. No:16. Cumulative % Release of Lercanidipine Hydrochloride Mouth 
Dissolving Tablets F5-F8 
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F5
F6
F7
F8
Time (mts) 
% Drug Release of Formulations 
F5 F6 F7 F8 
0 0 0 0 0 
1 35.47 39.67 43.82 44.34 
2 44.22 46.18 56.21 60.07 
4 56.03 59.72 63.49 72.18 
6 63.97 68.23 71.02 80.40 
8 71.08 73.70 79.08 89.72 
10 79.94 83.46 87.53 94.27 
12 86.28 90.24 93.15 99.42 
15 91.62 98.38 99.87 --- 
17 97.21 --- --- --- 
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Table. No:29. Cumulative % Release of Lercanidipine Hydrochloride 
Mouth Dissolving Tablets F9-F12 
 
Fig. No:17. Cumulative % Release of Lercanidipine Hydrochloride Mouth 
Dissolving Tablets F9-F12 
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F9
F10
F11
F12
Time (mts) 
% Drug Release of Formulations 
F9 F10 F11 F12 
0 0 0 0 0 
1 33.43 34.61 36.23 41.81 
2 45.96 49.14 51.78 59.76 
4 53.07 62.49 68.45 72.33 
6 64.23 71.93 79.17 85.87 
8 76.88 83.74 87.92 99.22 
10 89.26 92.57 97.48 --- 
12 98.75 99.22 --- --- 
15 --- --- --- --- 
17 --- --- --- --- 
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Table.No.30: Cumulative % Release of Lercanidipine Hydrochloride Mouth 
Dissolving Tablets F13-F16 
 
Fig.No.18: Cumulative % Release of Lercanidipine Hydrochloride Mouth 
Dissolving Tablets F13-F16 
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F13
F14
F15
F16
Time (mts) 
% Drug Release of Formulations 
F13 F14 F15 F16 
0 0 0 0 0 
1 12.29 19.74 21.35 24.21 
2 19.71 27.24 39.74 40.39 
4 29.37 36.42 44.64 53.91 
6 34.92 41.37 52.47 66.26 
8 41.24 51.79 61.88 75.54 
10 49.33 60.28 70.22 89.19 
12 58.76 69.96 76.34 93.65 
15 65.22 74.44 83.14 96.78 
17 71.24 80.94 89.47 98.37 
CHAPTER- 12                                                                RESULT AND DISCUSSION 
 
J.K.K.NATTRAJA COLEGE OF PHARMACY Page 95 
 
Fig.No.31: Graph: Cumulative % Release of Lercanidipine Hydrochloride 
Mouth Dissolving Tablets F12 
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8.9 STABILITY STUDIES: 
Table no. 26: Stability studies of optimized formulation F12 
 
Time    
( days) 
25oC ± 2oC/60% RH ± 5% RH, 30oC ± 2oC/65% RH ± 5% RH,  
40oC ± 2oC/75% RH ± 5% RH 
Hardness(kg/cm2) 
Drug 
content 
(%) 
%  Drug release DT 
30 2.23 99.11 99.29 36 
60 2.22 99.03 99.12 37 
 
➢ Stability studies were carried out on selected formulations (F12) as per 
ICH guidelines. There was not much variation in matrix integrity of the 
tablets at all the temperature conditions. There was no significant 
changes in drug content, physical stability, hardness, friability, drug 
release, for the selected formulation F12 after 90 days at 25oC± 20C / 
60% ± 5% RH, 300C ± 20C / 65% ±5% RH and 400C ± 20 / 75% ± 5% RH. 
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     13. SUMMARY AND CONCLUSION 
The present study involves formulation and evaluation of 
immediate release tablets of Lercandipine Hydrochloride. Endeavours 
with respect to Direct compression method used for formulating 
tablets was best suitable to achieve 100% results. 
Preformulation studies involving organoleptic bulk density, 
angle of repose, tapped density, compressibility index, hausner ratio, 
melting point range, pH and solubility were carried out as per USP 
specifications. 
Polymers such as CrosPovidone, Croscarmellose Sodium (CCS), 
Sodium Starch Glycolate (SSG), Starch 1500 were utilized in the 
trails. All the physical evaluations carried in preformulation studies 
were carried out on all the four different polymers utilized. All the 
formulations exhibited values within the acceptable range. 
Tablets were evaluated for weight variations, hardness, 
friability, thickness and Dissolution studies.  
 Release studies were carried out in Phosphate buffer, for 30 
minutes. Evaluated samples for all the three polymer systems. Results 
indicated that formulation F12, gave 99.14% release within 8 minutes 
which is formulated with CrosPovidone alone. Assay was carried out 
for formulation F12 and was found to be 99.42%.  
 Remaining formulations gave fluctuating release profiles. The 
formulation F12  was considered to be better among the trails 
accomplished. 
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